antioxidants

MDPI

Article

Integrative Proteomic and Bioenergetic Profiling Reveals Diet- and Strain-Specific Mitochondrial Dysfunction in Cohen Diabetic Rat Hearts

Lauren Pavelich [1,2,†], Tasnim Arroum [1,†], Lucynda Pham [1], Dragana Komnenov [3,4], Paul M. Stemmer [5], Rachel Lax [6,7,8], Ann Saada [6,9,10], Sarah Weksler-Zangen [6,7,8,‡] and Maik Hüttemann [1,2,*,‡]

1 Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI 48201, USA; laurenpavelich@wayne.edu (L.P.); ho0066@wayne.edu (T.A.); lucynda.pham@med.wayne.edu (L.P.)
2 Department of Biochemistry, Microbiology, and Immunology, Wayne State University, Detroit, MI 48201, USA
3 Department of Physiology, Wayne State University, Detroit, MI 48201, USA; dkomneno@med.wayne.edu
4 John D. Dingell VA Medical Center, Detroit, MI 48201, USA
5 Institute of Environmental Health Sciences, Wayne State University, Detroit, MI 48201, USA; pmstemmer@wayne.edu
6 Faculty of Medicine Hebrew, University of Jerusalem, Jerusalem 9112102, Israel; rachel.lax@mail.huji.ac.il (R.L.); ann.saadareisch@mail.huji.ac.il (A.S.); zangensarah@gmail.com (S.W.-Z.)
7 The Hadassah Diabetes Center, Hadassah Medical Center, Jerusalem 9112102, Israel
8 The Liver Research Laboratory, Hadassah Medical Center, Jerusalem 9112102, Israel
9 Department of Genetics, Hadassah Medical Center, Jerusalem 9112102, Israel
10 Department of Medical Laboratory Sciences, Hadassah Academic College, Jerusalem 9101001, Israel
* Correspondence: mhuttema@med.wayne.edu; Tel.: +1-313-577-9150
† These authors contributed equally to this work.
‡ Co-senior authors.

Abstract

Mitochondrial dysfunction contributes to diabetic cardiomyopathy, yet how genetic predisposition and diet interact to reshape cardiac metabolism in diabetic and prediabetic states remains unclear. The Cohen diabetic rat model, comprising diabetes-resistant (CDr) and diabetes-sensitive (CDs) strains, provides a unique platform to dissect this interplay. Here, we present an integrative global proteomic and bioenergetic characterization of cardiac tissue from CDr and CDs rats fed either a regular or a diabetogenic diet. Proteomic pathway mapping revealed downregulation of cytochrome *c* oxidase (C*c*O) subunits, strain-dependent rewiring of fatty-acid oxidation pathways, and C*c*O subunits switch from "heart-type" to "liver-type" isoforms in the sensitive strain. These changes were accompanied by impaired mitochondrial respiration, ATP depletion, and disruption of mitochondrial quality-control mechanisms, together with increased accumulation of tyrosine 304 phosphorylation of cytochrome *c* oxidase subunit I, indicative of inflammation-driven regulatory inhibition in a diet-specific manner. These findings establish an understanding of how genetic susceptibility and diet contribute to cardiac mitochondrial dysfunction in the Cohen diabetic rat model.

Keywords: cytochrome *c* oxidase; C*c*O6A; C*c*O7A; supercomplexes; regulation; phosphorylation; cardiomyopathy; mitochondrial dysfunction; tyrosine 304 phosphorylation; respiration; heart mitochondria; type 2 diabetes; mitochondrial quality control; proteomic characterization

Check for updates

Academic Editor: Ivan George Fantus

Received: 5 January 2026
Revised: 4 February 2026
Accepted: 10 February 2026
Published: 13 February 2026

Copyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.

1. Introduction

Mitochondria are essential organelles responsible for producing over 90% of cellular ATP through the oxidative phosphorylation (OXPHOS) system located in the inner mitochondrial membrane. OXPHOS is particularly vital in metabolically active tissues such as the heart, brain, liver, and skeletal muscle, which require substantial energy to sustain physiological processes and adapt to fluctuating energy demands. A decline in ATP production results in an energy deficit, compromising the ability of these tissues to effectively metabolize glucose and fatty acids [1]. The OXPHOS system comprises five multi-subunit enzymes and two small electron carriers, coenzyme Q and cytochrome *c*. Complexes I, III, and IV (cytochrome *c* oxidase, C*c*O) assemble into mitochondrial supercomplexes (SCs), forming higher molecular weight multi-enzyme structures. SCs exhibit various stoichiometric compositions, such as $I_{1\text{-}2}$ + III_2, III_2 + IV_1, and I + III_2 + $IV_{1\text{-}4}$ [2,3], which differ significantly across species and tissues, and their physiological importance remains a topic of debate [4,5].

Growing evidence suggests that SCs can act as independent entities capable of performing respiration [6–8]. SCs are generally proposed to be associated with enhanced respiration efficiency and reduced reactive oxygen species (ROS) production [9]. The regulation of mitochondrial ROS generation is crucial, as excess ROS contributes to cellular damage and aging [10]. Consequently, SCs are often proposed to be associated with improved mitochondrial function and cellular health [7,11]. Molecular changes that determine SC composition and distribution, such as the possibility of their regulation through posttranslational modifications (PTMs), in particular protein phosphorylation, have not been considered.

Protein PTMs are crucial and tightly controlled regulatory mechanisms, fine-tuning protein function and activity in response to cellular signaling and environmental changes. For example, C*c*O is the terminal and proposed rate-limiting enzyme of the electron transport chain (ETC) in mammals [12] and acts as a crucial regulatory checkpoint for mitochondrial respiration by catalyzing the reduction in molecular oxygen to water. Together with Complexes I and III, C*c*O generates the proton gradient across the inner mitochondrial membrane necessary for ATP synthesis. C*c*O activity is modulated through various mechanisms, including tissue-specific isoforms [13], allosteric regulation by the ATP/ADP ratio and thyroid hormones [14,15], and PTMs [12]. Previously, we showed that tyrosine 304 (Y304) of the catalytic subunit I of C*c*O can be phosphorylated via a cAMP-dependent mechanism and by inflammatory signaling in liver and lung tissue [16,17]. Y304 is located near the catalytic oxygen binding site of C*c*O subunit I and functions as a respiratory switch for enzyme activity. Phosphorylation of this tyrosine results in C*c*O inhibition and pronounced sigmoidal kinetics in the reaction with cytochrome *c* [16], leading to disruption of mitochondrial respiration and energy production [16,17]. Changes in the phosphorylation state of C*c*O within SCs may play an important role in regulating SC composition and the overall activity of SCs, and a mechanistic understanding of how SC activity is fine-tuned may help to further decipher their physiological role and their contribution to mitochondrial dysfunction. It is well established that impairment of mitochondrial function is associated with numerous metabolic diseases [18–22], contributing to disorders such as insulin resistance, heart failure, and diabetic cardiomyopathy. Among the most severe consequences of type 2 diabetes (T2D) are cardiovascular complications, which arise from the interplay of metabolic dysregulation, insulin resistance, and mitochondrial impairment [23]. Cardiomyocytes, which possess a high demand for ATP, are especially susceptible to the ramifications of mitochondrial dysfunction [24].

The healthy heart relies heavily on fatty acids to meet its high energetic demands, with 50–70% of ATP generated through fatty acid oxidation [25,26]. This dependence requires

precise regulation, as cardiomyocytes possess only a limited capacity for lipid storage. Under normal conditions, fatty acid uptake and oxidation are therefore carefully balanced to ensure a steady energy supply without accumulating excess lipids. It has been established that in diabetic hearts, this balance becomes disrupted, leading to an increase in fatty acid oxidation rates, lipid deposition within the heart, resulting in lipotoxicity, and thus causing mitochondrial dysfunction, diabetic cardiomyopathy, and inflammation [27–29].

Here, we investigated the effect of a high-sucrose low copper diet (HSD) on cardiac mitochondrial function using the Cohen rat model, developed through over 100 generations of selective inbreeding. This model includes two distinct strains: the Cohen diabetes-sensitive (CDs) rats, which develop T2D when exposed to an HSD but maintain normoglycemia on a regular diet (RD), and the Cohen diabetes-resistant (CDr) rats, which maintain normal blood glucose levels on both diets [30,31]. These strains provide a unique platform for exploring the interplay between dietary and genetic factors within metabolic disease [32]. Cardiac dysfunction is well established for the CDs rats, which have increased heart mass and develop cardiac hypertrophy with left-ventricular wall thickening, diffuse interstitial connective-tissue accumulation, and perivascular fibrosis in the left ventricle, contributing to stiffening and diastolic dysfunction [33,34]. The animals also present with ischemic necrosis foci and hyperplastic vascular changes in the myocardium [35]. In addition, when switched to the HSD, the hearts of hyperglycemic CDs rats failed to exhibit ischemic preconditioning-associated protection, a critical adaptive mechanism that preserves cardiac resilience during metabolic stress [36].

In previous studies, we showed that CDs rats demonstrated reduced C*c*O activity in several tissues [31,37–40]. In the present study, we show that HSD induces pathological remodeling of cardiac mitochondria, characterized by impaired bioenergetic function, decreased C*c*O activity, C*c*O isoform switching, disrupted mitochondrial quality control, proteomic changes, and activation of inflammatory signaling. We identified a diet-specific increase in the phosphorylation of C*c*O within cardiac respiratory SCs, and defective fatty-acid metabolism arising from genetic susceptibility in the diabetes-sensitive strain, collectively leading to mitochondrial dysfunction and energy depletion under metabolic stress.

2. Materials and Methods

2.1. Animal Information

Animal information was described in detail in [38] and heart tissue was derived from the same animals. Briefly, the Cohen rat diabetes model was developed by selective inbreeding of rat [30,31,38]. At 6 weeks of age, male Cohen diabetes-sensitive (CDs) and Cohen diabetes-resistant (CDr) were switched to a high-sucrose diet, which is also low in copper (HSD) for 6 weeks, or maintained on a regular chow-diet (RD; Teklad, Harlan Laboratories, Placentia, CA, USA) [40]. While systemic copper levels in diabetic patients can be elevated, studies indicate a paradoxical decrease in intracellular myocardial copper content or a functional deficiency within cardiomyocytes caused by defective cellular uptake and/or impaired intracellular trafficking of copper [41,42], which is mimicked by the diet. The HSD consisted of a custom-prepared diabetogenic diet comprising 72% sucrose, 18% vitamin-free casein, 5% salt mixture no. II USP (MP Biomedicals, Solon, OH, USA), 4.5% butter, 0.5% corn oil, vitamins, and low copper (1.2 ppm) [32]. Blood glucose levels 2 h post-oral glucose tolerance test and body weights were previously reported [38]. Rats were euthanized using an overdose of a combined ketamine/xylazine mixture, and hearts were immediately removed, flash-frozen in liquid nitrogen, and stored at −80 °C until processing. Animal experiments were approved under protocol number MD-22-16924-3 by the Institutional Animal Experiments Committee (IACUC).

2.2. Proteomic Analysis

Whole heart tissue lysates were processed for proteomic analysis using the EasyPep™ MS Sample Prep Kit (Thermo Fisher Scientific, Waltham, MA, USA, cat. no. A40006). A Thermo Scientific Orbitrap Eclipse Tribrid mass spectrometer, operated in data-dependent acquisition (DDA) mode, was used to identify peptides. Raw data files were processed using the MaxQuant platform (v2.6.8.0) and searched against the UniProt *Rattus norvegicus* reference proteome as described (https://www.uniprot.org/proteomes/UP000002494 (accessed on 25 February 2025)) in [43] for a simple data set. Subsequent data processing and statistical analysis were performed using the Perseus framework (v2.1.4.0) [44]. Briefly, protein groups annotated as "contaminants" or "reverse" were excluded. Label-free quantification (LFQ) intensity values were grouped into experimental conditions consisting of five biological replicates per (except CDr-RD, n = 4; each from a separate animal). Protein identifications were filtered to retain only those detected with $\geq$2 unique peptides and present in $\geq$70% of samples within at least one group. Proteins were filtered to include only those identified with $\geq$2 unique peptides and present in at least 70% of samples within one group. LFQ intensities were $\log_2$-transformed, and missing values were imputed using a Gaussian distribution-based method. Differential protein expression was assessed using a permutation-based ANOVA (multiple-sample *t*-test) with a false discovery rate (FDR) < 0.05. Data visualization included unsupervised principal component analysis (PCA) and hierarchical clustering heatmaps. Pathway enrichment analysis was performed using ShinyGO v0.82, focusing on proteins significantly affected by strain and/or diet, with significance defined as FDR < 0.05. Results were visualized as dot plots ranked by fold enrichment.

2.3. Heart Tissue Homogenization and Mitochondria Isolation

Homogenization was carried out using gentleMACs Dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany, cat. No 130-093-235) with the protocol m_lung_02.01. Heart tissue (70 mg) was added to 2 mL of mitochondrial isolation buffer (MIB: 200 mM sucrose, 10 mM Tris, 1 mM EGTA, pH 7.4 adjusted with 1 M HEPES solution, Gibco, Waltham, MA, USA, cat. no. 15630080) and placed in gentleMACs C Tubes (Miltenyi Biotec, cat. no. 130-093-237). The entire process was performed on ice to help preserve protein integrity and prevent dephosphorylation. To further breakdown the tissue, 0.4 mg of Subtilisin A (Protease) (Sigma, Burlington, MA, USA, cat. no. P5380) was added to the tissue homogenate and incubated at 4 °C for 10 min with gentle shaking. A series of filtration steps was done to enrich for mitochondrial fractions. A total of 2 mM phenylmethylsulphonylfluoride, 5 mM heat-activated sodium vanadate, and Protease Inhibitor Cocktail (Sigma, Cat. no. P8849) were added to the MIB. The filters were pre-wet with MIB. First, large cellular debris and nuclei were removed with a 40 M filter (pluriSelect, El Cajon, CA, USA, cat. no. 43-50040-50). The flowthrough containing mitochondria was filtered a second time through a 10 µM filter (pluriSelect cat. no. 43-50010-03) to further remove contaminants. To precipitate the crude mitochondrial fraction and further remove contaminants, the second flowthrough was then subjected to two medium speed centrifugations (9000× *g*, 15 min, 4 °C). Protein concentration was measured using the DC protein assay kit (Bio-Rad, Hercules, CA, USA, cat. no. 5000111) according to the manufacturer's protocol.

2.4. Cytochrome c Oxidase Activity Measurements Using the Polarographic Method

To measure respiration of heart mitochondria in the Cohen CDr and CDs rat strains, we measured C*c*O-specific activity using a Clark-type oxygen electrode (Oxygraph system, Hansatech, Norfolk, UK) as described in [38]. Briefly, for each measurement, 30 µg of total mitochondrial protein was used and resuspended in solubilization buffer (10 mM K-HEPES,

pH 7.4; 40 mM KCl; 1% Tween 20). Next, mitochondrial membranes were disrupted using a Fisher Scientific (Waltham, MA, USA) Sonic Dismembrator Model 100 ultrasonicator (2 rounds of 3 s pulses) at 4 °C. Oxygen consumption was assessed in the presence of 20 mM ascorbate and 30 µM cytochrome *c* (Sigma, cat no. C3131). Oxygen consumption rates were continuously monitored, and the data were recorded in nmol/min/mg mitochondrial protein and analyzed with the OxyTrace+ software (version 1.0 Build 48, 2016, Hansatech Instruments Ltd., Amesbury, MA, USA). The remaining sample was run on an SDS-PAGE to normalize the measurements to mitochondrial amount and C*c*O amount.

2.5. Mitochondrial Membrane Solubilization for BN-PAGE

The BN-PAGE protocol was adapted from [38,45]. All components were used from the NativePAGE™ Sample Prep Kit (ThermoFisher Scientific, cat. no. BN2008), including NativePAGE™ 4 × sample buffer, NativePAGE™ 5% G-250 sample additive, except the digitonin (ThermoFisher Scientific, cat. no. 407565000), which was diluted to 5%. Briefly, NativePAGE™ 4 × sample buffer supplemented with digitonin (5%) was used to reach a final concentration of 1.5% (digitonin/protein ratio of 6 g/g) to solubilize the mitochondria. To ensure complete solubilization of the mitochondrial membranes, the mixture was incubated on ice for 15 min and resuspended every 5 min. The mixture was then centrifuged at 4 °C at 17,000× *g* for 30 min to remove the membranes. After centrifugation, 0.5% G-250 sample additive was added to the supernatant. Next, 40 µg or 20 µg of these samples were loaded onto 3–12% native gradient gels (Invitrogen, Carlsbad, CA, USA, cat. no. BN1001BOX); 40 µg was used for in-gel activity assay, and 20 µg protein was used for immunoblotting. Electrophoresis was conducted at 4 °C, applying 150 V with light blue cathode buffer until the proteins entered 1/3 into the gel (~30 min), when the voltage was increased to 200 V and the clear cathode buffer (50 mM Tricine, 15 mM Bis-Tris, pH 7.0) was used. The gel ran for ~1 h to achieve the desired separation. One of the gels used for Western blot was stained with GEL Blue (Biosciences, St. Louis, MO, USA, cat. no. 786-35G) for 30 min. Before imaging, the gel was washed with water twice for 5 min. The other gel was left unstained. The mitochondrial proteins on the native gel were then transferred to a PVDF membrane (Bio-Rad, cat. no. 1620177) via a wet transfer at 10 V overnight. To help transfer large proteins, the transfer buffer (25 mM Tris base 192 mM glycine, 20% methanol, 0.05% SDS, pH adjusted to 8.3) contained 0.05% SDS.

2.6. Mitochondrial Native Protein In-Gel Activity Assay (IGA)

In-gel activity (IGA) assay was conducted after the BN-PAGE as described in [38]. Briefly, gels were immersed in the respective complex assay buffer (10 mL) at room temperature. C*c*O and complex I (CI) activity assays were conducted on separate gels. Both reactions were carried out at room temperature for ~1 h with gentle shaking and images were recorded every 15 min. Before imaging again, the gels were washed twice for 5 min in water. The gels were then imaged again the following day after being washed in water overnight at 4 °C. Pictures obtained after 1 h of incubation were used for quantification to avoid oversaturated signals.

2.7. Preparation of Tissue Lysates for SDS-PAGE

Twenty mg of heart tissue was homogenized with manual grinding with 200 µL of RIPA Buffer (150 mM NaCl, 1% Nonidet P 40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 8.0) with 1:100 protease inhibitor cocktail (PIC) for 5 min on ice. The samples were then sonicated using a Fisher Scientific Sonic Dismembrator Model 100 ultrasonicator (4 rounds of 5 s pulses) at 4 °C. Further, dilution in RIPA buffer was done if needed. Protein concentration was determined using the DC protein assay kit (Bio-Rad, cat. no. 5000111) according to the manufacturer's protocol.

2.8. SDS-PAGE

For C*c*O activity normalization, leftover isolated mitochondria from oxygen consumption readings (4 µg) were added to SDS-loading buffer (4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, 0.125 M Tris-HCl, adjusted pH to 6.8) and incubated for 20 min at 55 °C. Next, we loaded the samples onto mini-protean TGX precast gradient SDS-PAGE gels (4–15%) (Bio-Rad, cat. no. 4561085). In order to load all samples on the same gel, the first set was loaded into the gel, and the gel was run for 30 min at 100 V. The wells were then washed with fresh cathode buffer, and the next set of samples was loaded. The gel was then run for an additional 30 min at 100 V. This was followed by a wet transfer to a PVDF membrane (transfer buffer: 25 mM Tris base, 192 mM glycine, 20% methanol, pH adjusted to 8.3) at 10 V or rapid transfer using ready-to-assemble transfer kit (Bio-Rad, cat. no. 1704273) with Trans-Blot® Turbo™ Transfer System (Bio-Rad, cat. no. 1704150) at 2.5 A for 7 min. For total protein SDS-PAGE, ~30 ug were added to SDS-loading buffer (4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, 0.125 M Tris-HCl, adjusted pH to 6.8) and gently shaken at room temperature for 30 min. Samples were then boiled at 95 °C for 5 min. Next, the samples were loaded onto mini-protean TGX precast gradient SDS-PAGE gels (4–15%) (Bio-Rad, cat. no. 4561096) and run for 1 h at 120 V. This was followed by a wet transfer overnight to a PVDF membrane at 10 V.

2.9. Western Blot Analysis

A 15 min methanol wash step was performed to remove Coomassie dye in the cases where the membranes were stained. This was done to improve antibody binding. Membranes were washed 2 × 5 min with water and 2 × 5 min with TBST to remove methanol. Membranes were blocked with a blocking reagent (5% bovine serum albumin (BSA), 1% Tris-buffered saline with Tween-20: TBST, 0.1% Tween-20) for 45 min at room temperature. The primary antibody (Table 1) was added with gentle shaking for 90 min at room temperature or overnight at 4 °C. Membranes were washed twice for 5 min using TBST as the wash solution. Finally, membranes were incubated with the secondary antibody for 1 h at room temperature (Table 1). The membranes were imaged using Pierce™ ECL Western blotting Substrate (ThermoFisher, cat. no. 32106), and signals were recorded on ChemiDoc MP imaging system (Bio-Rad, Cat. no.12003154) or on an X-ray film. Production of our anti-pY304 C*c*O subunit I specific antibody is described in detail [16,38]

Table 1. List of antibodies used in this study.

Antibody	Dilution	Company	Product ID
MT-CO1 (C*c*O 1)	1:1000	Proteintech, Rosemont, IL, USA	PA5-68016
COXIV	1:1000	Proteintech	11242-1-AP
Core1	1:1000	Abcam, Waltham, MA, USA	Ab110252
SDHA	1:2000	Abcam	Ab14715
TOM20	1:1000	Cell Signaling Technology, Danvers, MA, USA	D8T2N
Custom-made pY304 C*c*O 1	1:1000	Abgent, San Diego, CA, USA	RB 96601
Beta-Actin	1:50,000	Proteintech	6008-1-Ig
NDUFS3	1:1000	Abcam	17D95
ATP5A	1:1000	Proteintech	14676-1-AP
PGC1α	1:1000	Abcam	AB191838
Alpha Tubulin	1:2000	Proteintech	11224-1-AP
TFAM	1:1000	Abcam	AB252432

Table 1. *Cont.*

Antibody	Dilution	Company	Product ID
MFN2	1:1000	Cell Signaling Technology	D2D10
SQSTM1/p62	1:500	Cell Signaling Technology	D6M5X
VDAC	1:1000	Cell Signaling Technology	4661S
SOD2	1:5000	Abcam	Ab13533
p-s616 DRP1	1:1000	Thermo Fisher Scientific	PA5-64821
DRP1	1:1000	Cell Signaling Technology	D6C7
SOD1	1:1000	Cell Signaling Technology	E4G1H
OPA1	1:1000	Proteintech	27733-1-AP
LC3B	1:1000	Cell Signaling Technology	E5Q2K
4-HNE	1:1000	Abcam	ab46545
Anti-Rabbit IgG HRP-linked	1:5000	Cell Signaling Technology	7074S
Anti-Mouse IgG HRP-linked	1:8000	Cell Signaling Technology	7076S
Anti-Rabbit IgG StarBright Blue 700	1:2500	Bio-Rad	12004162
Anti-Mouse IgG StarBright Blue 520	1:5000	Bio-Rad	12005867

2.10. ATP Measurements

ATP levels were assessed using the bioluminescent method in combination with the boiling method as described [38]. To normalize the ATP concentrations, samples were added to RIPA buffer and subjected to further sonication. The samples were allowed to self-pellet for 1–2 min, and the supernatant was then combined with SDS-loading buffer (4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, 0.125 M Tris-HCl, adjusted pH to 6.8). The samples were further incubated at room temperature while shaking for 15 min to ensure all the protein was denatured. Samples were then heated to 95 °C for 5 min and loaded onto an SDS-PAGE (10%) followed by an overnight wet transfer at 10 V. Western blotting was performed with β-actin.

2.11. RT-qPCR

RNA was isolated from ~50 mg of heart tissue using TRIzol™ Reagent (Invitrogen, cat. no. 15596026) and PureLink® RNA Mini Kit (Ambion, Waltham, MA, USA, cat. no. 12183018A), according to the manufacturer's protocol. RNA concentration was determined using NanoDrop One (ThermoFisher, cat. no. ND-ONE-W) with high purity (A_{280}/A_{260}~2.0 for all samples). Total cDNA was generated from RNA using iScript cDNA Synthesis kit (Bio-Rad, cat. no. 1708891) according to the manufacturer's protocol. qPCR reactions were conducted using PowerUp™ SYBR™ Green Master Mix (Applied Biosystems, Waltham, MA, USA, cat. No. A25776) based on the manufacturer's protocol. Plates (Applied Biosystems, cat. no. 4346906) were run using the 7500 Fast Real-Time PCR System (Applied Biosystems) based on the Life Technologies system set up with 45 cycles.

Primer sequences for rat

GAPDH Forward 5′-CCCCAATGTATCCGTTGTG-3′; Reverse 5′-CTCAGTGTAGCCC AGGATGC-3′ [46]

TNFa Forward 5′-AAATGGGCTCCCTCTCATCAGTTC 3′ Reverse 5′ TCTGCTTGGTG GTTTGCTACGAC-3′ [47]

CXCL2 (IL-8 analogue) Forward 5′-CATTAATATTTAACGATGTGGATGCGTTTCA-3′ Reverse 5′-GCCTACCATCTTTAAACTGCACAAT-3′ [48]

IL-1β Forward 5′-CCAAGCACCTTCTTTTCCTTCA-3′

Reverse 5′-AGCCTGCAGTGCAGCTGTCTAA-3′ [49]

CCL2 Forward 5′-TAGCATCCACGTGCTGTCTC-3′
Reverse 5′-CCGACTCATTGGGATCATCT-3′ [50]
IL-10 Forward 5′-TTGAACCACCCGGCATCTAC-3′
Reverse 5′-CCAAGGA GTTGCTCCCGTTA-3′ [51]

2.12. Dephosphorylation Experiment

To perform the dephosphorylation experiment, the complexes were freed from the inner mitochondrial membrane using our BN-PAGE mitochondrial solubilization protocol (see Section 2.5). After centrifugation, the supernatant was removed and diluted with water to 1 mg/mL. The reaction was carried out in a Clark-type oxygen electrode (Oxygraph system, Hansatech, Norfolk, UK) set at 37 °C with FastAP Thermosensitive Alkaline Phosphatase (Thermofisher, cat. No. EF0652) according to the manufacturer's protocol. Oxygen consumption was assessed in the presence of 20 mM ascorbate and 30 µM cytochrome *c* (Sigma, cat no. C3131) at the start of the reaction and 60 min into the reaction. The data were recorded in nmol/min/mg mitochondrial protein and analyzed with the Oxy-Trace+ software (version 1.0 Build 48, 2016, Hansatech Instruments Ltd., Amesbury, MA, USA). The remaining sample was run on an SDS-PAGE to normalize the measurements to mitochondrial amount and C*c*O amount.

2.13. Statistical Analysis

All data are presented as means ± SEM (standard error of the mean) values. To assess the differences between HSD and RD in both rat strains, i.e., Cohen diabetes-sensitive (CDs) and Cohen diabetes-resistant (CDr) rats, we conducted a two-way ANOVA followed by Tukey's multiple comparisons test. These statistical analyses were carried out using GraphPad Prism Version 10.3.0 for macOS (GraphPad Software, Boston, MA, USA) with significance level set at $p \leq 0.05$.

3. Results

3.1. Global Proteomic Remodeling and Inflammatory Signaling in the Hearts of Cohen Diabetic Rats

Although heart pathology is well characterized in the Cohen diabetic sensitive model, the underlying mechanisms are less clear. To identify pathways that may be altered by genetic background and diet and that lead to cardiac mitochondrial adaptations in the context of diabetic stress, we conducted unbiased data-dependent acquisition proteomic (DDA) analysis using cardiac tissue from CDr and CDs rat strains. While the Cohen diabetic rat model has been studied metabolically, a comprehensive comparison of their global cardiac proteomes under dietary stress has not previously been reported. Cardiac tissues were collected from both strains after feeding them a regular diet (RD) or a high-sucrose low-copper diet (HSD), a regimen known to promote type 2 diabetes (T2D) [40].

Figure 1A presents a heatmap of significantly altered proteins identified using permutation-based false discovery rate (FDR) correction. The most pronounced proteomic differences were observed between the HSD and RD groups in the CDs strain and between the strains, supporting their heightened susceptibility to dietary challenge in the CDs rats. Among the proteins associated with OXPHOS, components of cytochrome *c* oxidase (C*c*O, CIV) were, in particular, downregulated under HSD in both strains, such as C*c*O4I1 (Figure 1D; C*c*O4I1 plot) corresponding to ~49%, ~23%, and ~69% reductions in CDr-HSD, CDs-RD, and CDs-HSD, respectively, compared to CDr-RD. In addition, we confirmed previous studies reporting that the *Ndufa4* gene is deleted in the CDs strain [52,53] (Figure 1D; NDUFA4 plot). Although NDUFA4 was originally annotated as a Complex I (CI) subunit, it is now recognized as an accessory subunit of C*c*O [54]. NDUFA4 is not necessary for

C*c*O monomer assembly into supercomplexes. However, its deficiency has been associated with Leigh syndrome and metabolic disorders, and it could lead to lower C*c*O stability and activity [55,56]. In contrast, MT-ND1, a core mitochondrial-encoded subunit of CI located in the proton-pumping P-module of CI, was upregulated under HSD (Figure 1D; MT-ND1 plot), showing an opposite tendency to C*c*O4I1. It is important to note that, ATP synthase (complex V) subunits did not show a change in their expression pattern, as shown in Figure 1D; ATP5F1A plot.




Figure 1. Diet and strain-dependent global proteomic remodeling in Cohen diabetic rat hearts. (**A**) Heatmap of differentially expressed proteins across diet and strain; proteins were identified using permutation-based FDR correction set at 0.05. z-score–scaled proteomic analysis. (**B**) Pathway enrichment analysis (ShinyGO v0.82) was performed on differentially expressed proteins from diet and strain comparisons; significant pathways (FDR < 0.05) are shown as dot plots ranked by fold enrichment, and bubble size reflects the number of proteins enriched per pathway. (**C**) Network analysis of enriched metabolic pathways, illustrating functional relationships among altered pathways. (**D**) Fold change in protein expression pattern normalized to CDr-RD. ****, $p < 0.0001$; ***, $p < 0.001$; **, $p < 0.01$; *, $p < 0.05$ based on two-way ANOVA.

Interestingly, we identified switching of tissue-specific C*c*O isoforms by comparing heart-type (C*c*O7A1, C*c*O6A2) and liver-type (C*c*O7A2, C*c*O6A1) subunits (Figure 1D; C*c*O7A2/C*c*O7A1 and C*c*O6A1/C*c*O6A2 plot). The ratio of liver-type/heart-type revealed similar regulation patterns for C*c*O7A and C*c*O6A. For both isoform pairs, the ratio showed a shift toward the liver-type isoforms in the CDs-HSD group. The liver-type isoforms represent the fetal versions of the subunits, and the isoform switching would be consistent with the pattern seen for other genes during heart failure when fetal isoform genes are induced [57].

Several key enzymes involved in mitochondrial β-oxidation were consistently upregulated in CDs hearts, including ACADM (medium-chain acyl-CoA dehydrogenase, mitochondrial), ACAA2 (acetyl-CoA acyltransferase 2), HSD17B4 (17β-hydroxysteroid dehydrogenase type 4, peroxisomal), and ECI1 (enoyl-CoA delta isomerase 1, mitochondrial) (Figure 1D, ACADM, ACAA2, HSD17B4, and EC11 plot). This pattern was further amplified under HSD, suggesting a strain-dependent enhancement of lipid catabolism in response to dietary challenge. These results indicate a substrate shift toward medium and longer-chain fatty acids, a sign of increased fatty acid accumulation in the cardiac tissue, which potentially causes lipotoxicity and diabetic cardiomyopathy [27–29].

Notably, the upregulation of AK1 (adenylate kinase isoenzyme) (Figure 1D; AK1 plot) is an indicator of altered cellular energy state and increased adenylate turnover in the CDs strain, as the upregulation occurred in a strain-dependent manner, possibly caused by a lower ATP/ADP ratio and increased ATP demand in the CDs cardiac tissue.

Additionally, Venn diagram analysis (Figure 2C) comparing proteins significantly altered by diet alone versus strain alone uncovered distinct, non-overlapping sets of proteins associated with each factor, suggesting unique molecular responses to genetic background and dietary stress. The corresponding protein lists are provided in Table S1.

Pathway enrichment analysis of the biological processes predominantly enriched includes fatty acid metabolism, OXPHOS, and mitochondrial redox buffering systems (Figure 1B). Additionally, pathways associated with cardiac dysfunction, such as diabetic cardiomyopathy and cardiac muscle contraction, were significantly enriched when considering both diet and strain as combined factors (Figure 1B,C). To disentangle the individual contributions of diet and strain, we next performed pathway enrichment analyses using only proteins significantly altered by diet or strain alone. The results are summarized in Figure 2A–C and Supplementary Figure S1. Diet-driven enrichment revealed strong activation of pathways related to cardiac muscle contraction, diabetic cardiomyopathy, and OXPHOS dysregulation. Notably, acute-phase response protein haptoglobin (Hp), copper-binding protein ceruloplasmin (Cp), copper-binding glycoprotein, and heme-binding protein hemopexin (Hpx) were altered under HSD conditions, suggesting increased oxidative stress and disturbances in iron, copper, and heme homeostasis. Additionally, the upregulation of thiol protease inhibitor kininogen-1 (Kng1), involved in coagulation and inflammation, along with serpina3n, a serine protease inhibitor A3N linked to immune modulation in acute-phase response and response to cytokines, indicates a diet-induced pro-inflammatory response (heatmaps specific to diet effect vs. strain effect are shown in Figure 2A,B).




Figure 2. Distinct diet- and strain-dependent protein and inflammatory signatures in Cohen diabetic rat hearts. (**A**) Diet effect and (**B**) strain effect heatmaps. z-score–scaled proteomic analysis comparing regular diet (RD) and high-sucrose diet low copper (HSD) in Cohen diabetic sensitive (CDs) and resistant (CDr) strains. (**C**) Venn diagram comparing diet vs. strain-dependent proteomic differences (complete protein list provided in Table S1). (**D**) mRNA expression of inflammatory cytokines and chemokines in cardiac tissue measured by RT–qPCR. Total cDNA from CDr and CDs strain hearts was used. mRNA fold changes were normalized to GAPDH of IL-1β, CCL2, CXCL2 (IL-8 homolog), IL-1, and TNFα. Data were collected from at least 2 technical replicates and 4–5 animals per group. Data are represented as means ± standard error. ****, $p < 0.0001$; ***, $p < 0.001$; **, $p < 0.01$; *, $p < 0.05$ based on two-way ANOVA.

When focusing on strain-specific effects, we observe distinct enrichment in pathways related to fatty acid degradation, core metabolic processes (e.g., carbon and propionate metabolism), and modest enrichment of diabetic cardiomyopathy-related pathways, though to a lesser extent than the diet effect alone (Supplementary Figure S1A,B).

Principal Component Analysis (PCA) reveals that each animal group forms a distinct cluster, indicating that both diet and strain significantly influence the proteomic profile. Notably, animals on the HSD cluster toward the top of the plot, reflecting higher PC2 values,

whereas their RD counterparts are positioned lower on the PC2 axis. Additionally, the CDs-HSD group shows a more pronounced shift in proteomic profile compared to its RD counterpart, suggesting that the CDs strain exhibits a greater response to dietary changes than the CDr strain (Supplementary Figure S1C).

Together, our findings suggest that the CDs strain exhibits an inherent genetic susceptibility in protein pathways related to dietary stress, marked by disrupted OXPHOS function and enhanced fatty acid oxidation. When isolating the effects of diet, we observed a consistent molecular signature of mitochondrial dysfunction, alterations in cardiac muscle-specific pathways, and activation of inflammatory and stress response pathways.

Based on the proteomic data and to further investigate the presence of inflammation in our animal model, we conducted RT-qPCR using total cDNA generated from heart RNA of CDr and CDs animals. Our results show that HSD increases TNFα endogenous mRNA levels in both CDr and CDs strains' heart tissue about 4-fold on HSD compared to their respective RD groups (Figure 2D; TNFα plot), with diet being the only significant contributing factor. CXCL2 (IL-8 homolog) mRNA levels showed a 3-fold increase in CDr-HSD compared to RD and no statistically significant increase in CDs-RD or HSD, indicating both diet and strain as contributing factors (Figure 2D; CXCL2 plot). IL-1β mRNA levels increased approximately 6-fold in CDs-HSD compared to RD (Figure 2D; IL-1β plot). The results show that both factors are significant, with diet being the most influential. CCL2 exhibited a 5-fold increase in CDr-HSD versus RD and a 3-fold increase in CDs-HSD compared to RD (Figure 2D; CCL2 plot). Diet was the highest contributor for CCL2. In addition to pro-inflammatory cytokines, we also tested the anti-inflammatory cytokine IL-10 and found no change in its mRNA levels (Figure 2D; IL-10 plot). These findings indicate that the HSD increases pro-inflammatory signaling in both CDr and CDs animals. However, it appears that the strain is a contributing factor in determining which specific cytokine or interleukin is increased.

3.2. Complex IV Activity and ATP Decline in a Diet- and Strain-Dependent Manner

Due to its central role in mitochondrial respiration, C*c*O is tightly regulated via tissue-specific isoforms, allosteric control, and PTMs [12,16]. We previously demonstrated that C*c*O activity is significantly reduced in pancreatic β-cells of normoglycemic CDs rats fed a RD. When exposed to HSD, C*c*O function was further diminished, leading to reduced insulin secretion and diabetic onset [31,39]. Similarly, in the liver of both CDr and CDs rats, HSD resulted in reduced C*c*O activity, increased inhibitory phosphorylation of the dimeric form of C*c*O, and decreased ATP production [38]. However, the potential impact of HSD-driven diabetic maladaptation of mitochondrial function in other vital tissues, such as the heart of CDr and CDs rats, remained unknown.

To examine the impact of diet and strain variation on mitochondrial heart function, we first measured the oxygen consumption rate (OCR) of C*c*O after the purification and solubilization of mitochondria using a Clark-type electrode (Figure 3A,B). When C*c*O activity was normalized to total mitochondrial content (TOM20), CDr-HSD and CDs-HSD animals showed ~65% and ~54% lower OCR, respectively, compared to their RD-fed controls (Figure 3A). To determine whether the observed decrease in OCR was also due to functional inhibition of C*c*O enzyme activity rather than merely a reduction in the overall amount of C*c*O, we normalized C*c*O activity to the C*c*O enzyme amount (Figure 3B). OCR reduction persisted and we observed a ~65% decrease in CDr rats fed an HSD compared to CDr-RD rats. Interestingly, CDs rats showed strongly decreased C*c*O activity independent of diet, similar to that seen in CDr rats on an HSD. Strain was the highest contributor, but diet and their interaction were also statistically significant contributors to changes in C*c*O-specific activity.




Figure 3. C*c*O activity and ATP amount are reduced following the HSD in CDr and CDs rats. Isolated rat heart mitochondria were sonicated and analyzed with a Clark-type electrode in the presence of 30 µM cytochrome *c* to determine C*c*O-specific activity. (**A**) OCR was normalized to total mitochondrial amount (TOM20). (**B**) OCR was normalized to C*c*O amount (C*c*OIV). Data were collected from three independent experiments using mitochondria from five different rat hearts per group. Data are reported as % of CDr-RD set to 100% nmol O_2 consumption/min/mg mitochondrial protein. (**C**) Total protein lysate from heart tissue was run on SDS-PAGE. (**D**) Quantification of ATP5A normalized to SDHA. (**E**) Quantification of C*c*OIV normalized to SDHA. (**F**) ATP readings were normalized to β-Actin. RD, regular diet; HSD, high-sucrose-low copper diet. Data were from 5 animals per group. Data are represented as means ± standard error. ****, $p < 0.0001$; ***, $p < 0.001$; *, $p < 0.05$ based on two-way ANOVA.

Immunoblotting revealed substantial reductions in C*c*O content in both HSD-fed groups (Figure 3C). Specifically, CDr-HSD and CDs-HSD hearts showed 55% and 45% less C*c*O protein, respectively, compared to their RD counterparts. Notably, even under RD conditions, CDs rats had ~30% lower C*c*O content than CDr, indicating a strain-specific difference independent of diet (Figure 3E). Both loss of C*c*O protein and enzymatic inhibition contributed to the observed respiratory decline. Consistent with these findings, cardiac ATP levels were markedly reduced. CDr-HSD hearts exhibited an ~85% reduction compared to RD, while both CDs-RD and CDs-HSD showed ~90% ATP depletion relative to CDr-RD (Figure 3F). Levels of ATP synthase remained unchanged (Figures 1D and 3D ATP5F1A plot from proteomic analysis), suggesting impaired proton flux, rather than changes in ATP synthase expression, as the primary driver of ATP depletion. These data support the concept that both genetic predisposition and dietary challenge contribute to compromised mitochondrial respiratory capacity. The measured C*c*O activity reduction cannot only be explained through C*c*O content reduction but also through a decrease in C*c*O enzymatic turnover rate.

3.3. Tyrosine Phosphorylation Accumulates on CIV Within Dimers and Supercomplexes and Suppresses Regulation and Reorganization

Consistent with our RT-qPCR data, it has been shown that T2D in rats leads to a chronic low-grade inflammatory state [58]. We previously found that treating liver tissue with proinflammatory cytokine TNFα led to decreased C*c*O activity that correlated with an increase in Y304 phosphorylation on C*c*O subunit I [17]. C*c*O-I Y304 phosphorylation inhibits enzyme function and induces sigmoidal kinetics typically associated with dimerization [16,17]. We also previously reported elevated Y304 phosphorylation and reduced C*c*O activity in the livers of diabetic Cohen rats [38]. In this study, we extended our investigation to the heart to determine whether Y304 phosphorylation is specific to the liver or if it is also present in the heart, suggesting it may play a more global role in mitochondrial dysfunction in more than one tissue.

Using BN-PAGE followed by immunoblotting (Figure 4A,C) and in-gel activity (IGA) assays (Figure 4B,D; note that brown color indicates CIV activity and violet color indicates CI activity and not protein amount), we assessed C*c*O phosphorylation and function in cardiac mitochondria. A custom phospho-specific antibody targeting C*c*O-I-pY304 revealed significant increases in phosphorylation across multiple conditions (Figure 4A,C). Compared to CDr-RD, dimeric C*c*O showed a 120% increase in CDr-HSD, a 150% increase in CDs-RD, and a ~400% increase in Y304 phosphorylation in CDs-HSD (Figure 4E).

We also detected inhibitory phosphorylation of C*c*O in high-molecular-weight supercomplexes (SC_{pY304}) (Figure 4F). Notably, SC_{pY304} was already present in CDs-RD, suggesting a "primed" phosphorylation state even in the absence of dietary stress. Functionally, Y304 phosphorylation was strongly associated with enzymatic suppression (Figure 4B,D). C*c*O activity in SC_{pY304} complexes was decreased in CDs-HSD hearts (50%) (Figure 4H), while dimeric C*c*O activity declined by 25% in CDr-HSD and 42% in CDs-HSD compared to RD-fed counterparts (Figure 4I). Monomeric activity was also reduced in both HSD-fed groups (Supplementary Figure S3A). These findings support the hypothesis that Y304 phosphorylation inactivates C*c*O, particularly within supercomplexes in heart mitochondria (Figure 4A,C,H). In contrast, Complex I (CI) activity increased significantly under the same conditions. CDs-HSD rats exhibited a 54% increase in monomeric CI activity relative to CDr-RD (Supplementary Figure S3C), along with elevated CI activity in SC_{pY304}-containing bands (Supplementary Figure S3G). Additionally, CI activity in $I_2 + III_2$ supercomplexes rose by 25% and 30% in CDs-RD and CDs-HSD, respectively, compared to their CDr counterparts (Supplementary Figure S3H). These results suggest that increased CI activity may act as a compensatory response to CIV dysfunction.




Figure 4. HSD induces tyrosine 304 phosphorylation of C*c*O subunit I and inhibits its activity. (**A**,**C**) Blue Native PAGE (BN-PAGE) followed by Western blotting using anti–C*c*O-I (**left**) and anti–C*c*O-I-pY304 (**right**) antibodies for the CDr (**A**) and CDs (**C**) rat strains. (**B**,**D**) In-gel activity (IGA) assay for Complex IV (CIV) and Complex I (CI) following BN–PAGE for CDr (**B**) and CDs (**D**). Brown bands indicate C*c*O enzymatic activity (CIV), and violet bands indicate CI enzymatic activity. # (blue colored annotation) indicates statistically significant bands. (**E**,**F**) Quantification of pY304 signals normalized to total C*c*O-I: (**E**) Dimeric C*c*O-pY304, (**F**) Supercomplex-associated pY304 (SC_{pY304}). (**G**) k-means clustering of total pY304 signal versus normalized OCR per C*c*O amount. Three clusters were identified: cluster 1: CDs-HSD, cluster 2: CDr-RD, cluster 3: CDr-HSD and CDs-RD. Dot size reflects pY304 level. Both X and Y axes represent percent values relative to CDr-RD. (**H**,**I**) Quantification of CIV IGA activity: (**H**) SC_{pY304} activity, (**I**) CIV_2 activity 40 µg of mitochondria

per lane. Data were from 5 animals per group. (**J**–**M**) OCR measurements after alkaline phosphatase–mediated dephosphorylation (**J**) CDr-RD, (**K**) CDr-HSD, (**L**) CDs-RD, (**M**) CDs-HSD. Data was from 3 animals per group. Data are represented as means ± standard error. ****, $p < 0.0001$; ***, $p < 0.001$; **, $p < 0.01$; *, $p < 0.05$ based on two-way ANOVA.

To further explore the relationship between C*c*O function and total pY304 status, we performed correlation analysis and unsupervised k-means clustering using total C*c*O-I pY304 and C*c*O activity across all groups (Figure 4G). Three distinct metabolic clusters emerged: (1) CDr-RD, (2) CDr-HSD + CDs-RD, and (3) CDs-HSD. These clusters reflected a graded loss of mitochondrial function associated with increased phosphorylation. Importantly, in CDs-HSD, total phosphorylation predicted C*c*O inhibition ($R^2 = 0.735$), supporting a mechanistic link between PTM level and respiratory dysfunction. A moderate correlation was observed in CDr-HSD ($R^2 = 0.441$). Conversely, in CDs-RD ($R^2 = 0.010$), phosphorylation did not correlate with C*c*O activity, suggesting that genetic predisposition alone is insufficient to drive respiratory impairment through inhibitory phosphorylation. Together, these findings support a model in which both strain susceptibility and dietary stress converge to promote phosphorylation-dependent C*c*O inhibition.

To confirm that phosphorylation of Y304 was leading to the decrease in C*c*O activity, we performed a dephosphorylation experiment using alkaline phosphatase and isolated mitochondria. To directly access oxygen consumption and C*c*O activity, the dephosphorylation experiment was performed in the Clark-type electrode. C*c*O maximum turnover was assessed at time point zero (T0) and 60 min (T60) into the reaction. When normalized to C*c*OIV levels, we observed a significant increase in C*c*O activity at T60 in CDr-HSD (~80%), CDs-RD (~50%), and CDs-HSD (~105%) compared to T0. This suggests that the elevated phosphorylation in the animals fed a HSD was leading to a decrease in C*c*O activity, and by removing the phosphorylations, some of the C*c*O activity could be restored (Figure 4J–M). However, we were unable to recover the decrease due to the genetic predisposition (with decreased C*c*O levels) present in the CDs animals. Finally, the dephosphorylation reaction and alignment of pY304 immunoblots with C*c*O IGA demonstrated that elevated phosphorylation coincided with gel regions of C*c*O activity loss (Figure 4A,C,J,K).

To determine the molecular composition of the novel SC_{pY304} band observed in Figure 3B,D,F and Supplementary Figure S3A,B, we performed BN-PAGE followed by immunoblotting using a combination of phospho-specific and fluorescently multiplexed antibodies. Although technical limitations prevented multiplexing of our anti-CcO-I-pY304 antibody, due to the high hydrophobicity of C*c*OI, we successfully aligned the pY304 signal with the total C*c*O-I on the same blot, enabling accurate positional mapping (Supplementary Figure S5A).

To identify co-migrating complexes, we performed dual-channel fluorescent immunoblotting for C*c*O-I together with either CORE1 (Complex III) or NDUFS3 (Complex I) (Supplementary Figure S5B,C). Notably, SC_{pY304} co-migrated with NDUFS3-positive bands, confirming the presence of Complex I. In contrast, no CORE1 signal was detected in this region, indicating the absence of Complex III. The SC_{pY304} band partially overlapped with the migration zone of the canonical I + III_2 supercomplex but lacked CIII content, suggesting that this structure represents a potential non-canonical I + $IV_{1/2}$ supercomplex and/or IV_n aggregates that may be formed under stress conditions such as phosphorylation or high-sucrose exposure (Supplementary Figure S5A–C).

We next examined how strain and diet affected CI assembly and its distribution across SCs. Immunoblot analysis of NDUFS3 revealed an increase in monomeric CI as well as in the putative I + $IV_{1/2}$ supercomplexes (Supplementary Figures S5D and S6C quantification is summarized in the visual map image in Supplementary Figure S5G).

The I_2 + III_2 supercomplex also increased by over 200% in both CDs-RD and CDs-HSD compared to CDr-RD, while no significant change was observed between CDr-RD and CDr-HSD (Supplementary Figure S5G, quantified in Supplementary Figure S3F). Total CI levels were elevated in the CDs strain relative to CDr-RD (quantified in Supplementary Figure S6G; the two-way ANOVA results are summarized in Supplementary Table S2).

For CIII, CORE1 immunoblotting showed increased levels of the $CIII_2$ dimer in CDs rats compared to CDr (Figure 4E, quantification in Supplementary Figure S6H). Interestingly, the $CIII_2$ + IV complex was reduced in CDs-RD animals (Supplementary Figure S6I), despite no significant change in total CIII levels (Supplementary Figure S6N). Additionally, CIII content within the I_2 + III_2 supercomplex increased by ~85% in CDs-HSD compared to CDr-RD (Supplementary Figure S6M). These findings suggest that strain is the predominant factor influencing CI and CIII organization.

Together, these results reveal that both genetic background and dietary environment contribute to the remodeling of mitochondrial respiratory complexes. Specifically, they support the emergence of a stress-induced, non-canonical I + $IV_{1/2}$ supercomplex and/or IV_n aggregates (SC_{pY304}) lacking Complex III and altered SC stoichiometry involving Complex I and III, particularly in the diabetes-prone CDs strain.

3.4. High Sucrose Diet Induces Changes in Mitochondrial Biogenesis, Antioxidants, and Quality Control Mechanisms

Based on our proteomic data and qPCR, it appears that there is an increased susceptibility to genetic stress and OXPHOS dysfunction. Stress, including cardiovascular disease and T2D, can contribute to dysfunctional mitochondrial quality control as seen by changes in biogenesis, mitophagy, and autophagy [59]. To further investigate this, we used total protein lysate from heart tissue for immunoblotting with different quality control markers to see if there was an effect caused by differences in strain and/or diet (Figure 5A,H). We first investigated markers of quality control linked to mitochondrial dynamics (fission and fusion) and autophagy/mitophagy. We found an increase in fusion (Mitofusin 2, MFN2, and OPA1) and a decrease in fission markers (active Dynamin-related protein 1, pS616 DRP1) in the CDs strain, indicating impaired mitochondrial dynamics (Figure 5A). For MFN2, there was a 60% increase in CDs-RD compared to CDr-RD, and a 90% increase in CDs-HSD compared to CDr-RD (Figure 5C). The increases in MFN2 are statistically significant when normalized to VDAC (Supplementary Figure S7A), indicating a mitochondrial mass-independent increase. For OPA1, although not statistically significant, there was a trend of increased protein levels in the CDs strain (Figure 4D). For active DRP1 (p-S616 DRP1), there was a ~40% decrease when comparing CDs-RD and CDs-HSD to CDr-RD (Figure 5E). The results show that only the strain contributes to these alterations.

We next examined markers associated with autophagy and mitophagy. There was a decrease in autophagy markers (microtubule-associated protein light chain 3, LC3) and an increase in mitophagy pathways (sequestosome 1, SQSTM1/p62), suggesting impaired mitochondrial turnover. We found a decrease in the ratio of LC3 II to LC3 I (Figure 5F), with the only statistically significant decrease being a 75% drop in CDs-HSD compared to CDr-RD. There was also an increase in SQSTM1/p62 in the CDs strain (Figure 5G), with an 82% increase in the CDs-RD compared to the CDr-RD group and a 78% increase in CDs-HSD compared to CDs-RD group. In summary, there is an increase in mitophagy signaling but a decrease in autophagy in the CDs group under RD and HSD with the CDs-HSD group showing the most significant changes. This could indicate that mitochondria are labeled for degradation, but degradation is not executed, leading to the accumulation of damaged mitochondria.




Figure 5. Strain-dependent alterations in mitochondrial dynamics, mitophagy, biogenesis, and antioxidant responses in cardiac tissue. Total protein lysates from hearts of CDr and CDs rats were analyzed by SDS-PAGE followed by immunoblotting. (**A**)Representative western blot image of mito-

https://doi.org/10.3390/antiox15020248

phagy and autophagy markers. (**B**) Proposed model depicting alterations in mitochondrial quality control pathways in the CDs strain and amplified by diabetogenic diet. Quantification of protein levels normalized to tubulin: (**C**) quantification of MFN2, (**D**) total OPA1, (**E**) Phospho-DRP1 (Ser616) normalized to total DRP1 and tubulin, (**F**) LC3-II to LC3-I ratio, (**G**) p62/SQSTM1. Representative Western blot images of mitochondrial biogenesis and antioxidant markers. (**H**) Representative western blot image of mitophagy and autophagy markers. (**I**) Quantification of TFAM normalized to VDAC; quantification of protein levels normalized to Tubulin for (**J**) VDAC, (**K**) PGC1α, (**L**) SOD1, (**M**) SOD2, and (**N**) 4-HNE. Data were collected from 5 animals per group. Data are represented as means $\pm$ standard error. ****, $p < 0.0001$; ***, $p < 0.001$; **, $p < 0.01$; *, $p < 0.05$ based on two-way ANOVA. Note: TFAM, VDAC, and PGC1α were analyzed on the same blot; SOD1, and Phospho-DRP1 were analyzed on the same blot; SOD2, VDAC, MFN2, and p62 were analyzed on the same blot; and OPA1, LC31, and DRP1 were analyzed on the same blot.

To study mitochondrial biogenesis, we analyzed mitochondrial transcription markers and observed an increase in mitochondrial transcription factor A (TFAM) and mitochondrial biogenesis marker (peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PGC1α), but no change in mitochondrial mass (voltage-dependent anion channel, VDAC) (Figure 5H). Surprisingly, TFAM was increased 60% and 25% in the CDs-HSD group compared to CDr-RD and CDs-RD, respectively (Figure 5I). No significant change was observed in the CDr rats on RD and HSD (Figure 5H,I). However, when TFAM protein levels were normalized to VDAC, there was no increase compared to CDr-RD, suggesting that the increase in TFAM was due to an increase in mitochondrial mass. There was a trend for increased VDAC amounts in CDs-HSD compared to CDr-HSD hearts ($p = 0.097$) (Figure 5J). Additionally, we found a strong 385% and 60% increase in PGC1α protein levels in CDs-HSD compared to CDr-RD and CDs-RD, respectively, and a 145% increase in CDs-RD compared to CDr-RD (Figure 5K). No differences were noted between the CDr-HSD and CDr-RD groups.

Lastly, we found changes in antioxidant levels. Superoxide dismutase 1 (SOD1), a cytoplasmic ROS scavenger, showed a trend (45% decrease; not significant) in CDs-HSD compared to CDr-RD, and both the CDr-HSD and CDs-RD showed a trend (20% decrease, not significant; Figure 5L). In contrast, superoxide dismutase 2 (SOD2), which is a ROS scavenger localized to the mitochondrial matrix, was increased by 70% in CDs-HSD compared to CDs-RD, whereas the CDr-RD, CDr-HSD, and CDs-RD groups showed no statistically significant differences (Figure 5M). 4-HNE is a marker for lipid peroxidation, which reflects the levels of oxidative damage. 4-HNE levels were only significantly increased in CDs-RD compared to CDr-RD (150%) (Figure 5N). The higher levels of SOD2 in CDs-HSD may account for the lower levels of 4-HNE signal. Interestingly, the strain factor was the primary contributor to the observed differences in mitochondrial biogenesis and antioxidant markers.

These findings suggest that CDs animals have increased fusion, decreased fission, and defective autophagy (summarized in Figure 5B). Altogether, there are strain-dependent alterations in mitochondrial biogenesis, antioxidant levels, mitophagy, and autophagy that may contribute to diabetic cardiovascular disease.

4. Discussion

Diabetes is among the top risk factors for cardiovascular disease. This vulnerability is evident in diabetic cardiomyopathy, a condition characterized by left ventricular dysfunction, cardiac remodeling, and an elevated risk of heart failure independent of conventional cardiovascular risk factors [60,61]. Diabetic cardiomyopathy can occur in both type 1 and type 2 diabetes, with type 2 diabetes accounting for 90–95% of cases [62]. Furthermore, mitochondrial dynamics, including biogenesis, fragmentation, and mitophagy,

are altered in diabetic cardiomyopathy, exacerbating impairments in cardiac efficiency and function [63–67]. It is therefore essential to reveal diabetes-induced molecular changes to identify enzymes and pathways that can be targeted to improve cardiac function.

Fatty acids are critical oxidation substrates for the heart [26]. Our proteomics analysis revealed that genetic background profoundly shapes how cardiac mitochondria respond to dietary stress in the Cohen model. In the diabetes-sensitive CDs strain, core enzymes of mitochondrial and peroxisomal β-oxidation, ACADM, ACAA2, HSD17B4, and ECI1, were consistently upregulated, which may suggest increased utilization of fatty acids; however, this can also occur as an adaptive response to impaired fatty acid oxidation. This remodeling was further amplified under HSD, suggesting a diet-responsive enhancement of fatty-acid catabolism. This pattern is consistent with prior reports showing enhanced cardiac fatty-acid oxidation in diabetes and insulin resistance [68–70]. Such upregulation may represent a compensatory mechanism to handle elevated lipid availability and prevent the accumulation of toxic lipid intermediates. This adaptation in CDr hearts could explain their increased resilience in comparison to CDr-HSD liver mitochondria. However, in addition to changes in protein levels, regulation of fatty acid oxidation also depends on post-translational modifications, such as acetylation of important enzymes such as long-chain acyl-CoA dehydrogenase, which can inhibit long-chain fatty acid metabolism [71,72]. Further studies are needed to define the specific alterations of the fatty acid metabolic pathways in the Cohen model. We also validated previous studies that found a deletion of the *Ndufa4* gene in the CDs strain [52,53] and found further diet and strain-specific maladaptations as contributing factors explaining the pathologies found in the Cohen diabetic rat model. The loss of NDUFA4 (also referred to as COXFA4 [73]) was found to reduce C*c*O activity [54].

Proteins involved in the acute-phase response and redox homeostasis were dysregulated under HSD, including Hp (haptoglobin), Cp (ceruloplasmin), and Hpx (ceruloplasmin). These molecules are critical for iron and heme scavenging (Hpx) [74], copper transport (Cp) [75], and oxidative damage mitigation (Hp) [76], suggesting that the HSD induces systemic and cardiac oxidative stress and perturbs metal homeostasis. Moreover, the upregulation of Kng1 (kininogen-1) and serpina3n (serine protease inhibitor A3N), two proteins linked to coagulation, inflammation, and cytokine signaling, further supports a diet-induced pro-inflammatory state. Together, these findings indicate that HSD imposes a combined oxidative, inflammatory, and metal-dyshomeostasis burden on the cardiac tissue.

We showed previously that in vitro treatment of liver and pancreatic tissue with TNFα and IL-1β leads to C*c*O inhibition [17,31]. We propose that HSD induces an inflammatory state, triggering a signaling cascade that activates an unknown mitochondrial tyrosine kinase to phosphorylate C*c*O, resulting in its dimerization and subsequent inactivation in heart tissue. TNFα and IL-1β are implicated in the development of atherosclerotic plaques and heart failure [77,78], suggesting that these signaling pathways play an important role in the pathology of diabetic hearts. We also explored the role of cytokines such as CCL2 and CXCL2 that are involved in early and late inflammatory responses. CCL2 is associated with chronic low-grade inflammation frequently observed in T2D, while CXCL2 is linked to acute inflammation [79]. Our analysis indicates that within the Cohen rat model, the diabetes-sensitive CDs strain on an HSD shows patterns corresponding to later stages of heart failure and the manifestation of a type 2 diabetic phenotype, whereas the diabetes-resistant CDr strain on the same diet exhibits traits indicative of early-stage heart disease caused by mitochondrial dysfunction despite still being normoglycemic after six weeks on an HSD. Accumulations of p62 and decreased levels of LC3-II in unstable atherosclerotic plaques signify impaired mitophagy, which is also evident in diabetic cardiomyopathy, where changes in cardiac composition contribute to heart failure [59]. Other studies have

found that PGC1αlevels are increased in T2D, as it can directly increase cardiac fatty acid oxidation [28,69].

In previous studies, we demonstrated that Y304 in the catalytic subunit I of C*c*O acts as a regulatory switch through phosphorylation [16,17]. Phosphorylation at this site inhibits C*c*O and produces pronounced sigmoidal kinetics [16] as a means to regulate and fine-tune enzymatic activity. We recently reported that the livers of Cohen diabetic rats exhibited decreased C*c*O activity alongside increased Y304-C*c*O-I phosphorylation, particularly in the dimeric form of C*c*O within the diabetic liver tissue [38]. Interestingly, comparing those results with this study shows a distinct impact of diet and strain when contrasting mitochondria from the liver and heart. This underscores the different susceptibility of various tissues to diet and strain as disease modifiers [31]. Notably, CDr livers [38] seem more negatively affected than CDr hearts. In liver mitochondria, there was an 80% reduction in OCR for CDr rats on HSD compared to RD [38], while heart mitochondria in this study showed a 65% decline when comparing CDr-RD with CDr-HSD. Both liver and heart are affected by insulin resistance; however, heart tissue appears to have a somewhat protective mechanism against the inactivation of C*c*O in the context of T2D and inflammation. The liver is more severely affected in its metabolic function, while cardiac tissue is primarily structurally impacted and found to be more resistant to metabolic changes under hyperglycemic conditions [80]. These differences between the heart and liver may be explained by their distinct energy metabolism. Mitochondrial fatty acid oxidation constitutes about 60–80% of the mitochondrial substrate for cardiac ATP production [81], whereas liver, in the fed state, relies predominantly on glucose metabolism [82].

pY304-C*c*O-I accumulated not only in the dimeric C*c*O, but also in a subset of SCs—specifically, IV_n or $I + IV_{1/2}$. IV_n has previously been reported [83]; however, they run much lower (between IV_2 and $III_2 + IV$) compared to our gel region. The aggregates reported in our study could contain more copies of CIV (5–6 copies based on molecular weight). The latter SC was recently reported in two independent studies [84,85] and discussed by Cogliati et al. [6]; however, the function of this specific supercomplex remains unknown. Similar to our findings, I + IV was reported to co-migrate alongside free Complex I and $I + III_2$, and $I + IV_2$ runs close to $I + III_2$. In this study, we show that both dimeric C*c*O (IV_2) and $I + IV_{1\text{-}2}$ undergo increased phosphorylation in diabetic conditions ($IV_{2\,pY304}$ and $I + IV_{1/2\,pY304}$ or IV_n), resulting in an inhibition of C*c*O activity. This is paralleled by increased activity and protein levels of $I_2 + III_2$ and monomeric complex I, predominantly observed in diabetes-sensitive strain CDs on an HSD. Recent reports suggest that the formation of $I_2 + III_2$ provides protection against ischemic heart failure by reducing ROS production and stabilizing mitochondrial function [2]. Additionally, the structural integrity of SCs, such as complex I + IV and $I + IV_2$ raises questions regarding potential structural in addition to functional roles, highlighting the intricacies of the mitochondrial ETC architecture [83]. pY304-C*c*O-I is known to correlate with reduced enzymatic activity, and its accumulation within mitochondrial supercomplexes suggests that a subset of SCs may become selectively inhibited through this PTM under inflammatory conditions, such as that which is seen in diabetes.

In addition to PTMs and SCs, tissue-specific subunit isoforms of C*c*O finetune C*c*O activity. In human heart and skeletal muscle, there are two known tissue-specific isoforms, C*c*O6A2 and C*c*O7A1 (the "heart-type" isoform, also called COX6AH and COX7AH), which are distinct from their ubiquitously expressed counterparts, C*c*O6A1 and C*c*O7A2 (the "liver-type" isoform, also known as COX6AL and COX7AL; note that the numbering of the heart and liver isoforms is the opposite for C*c*O subunits 6A and 7A) [12]. In rodents and other mammals but not in humans, there is a third heart/liver isoform pair of the smallest C*c*O subunit 8 [13,86]. These subunits experience a developmental transition from the

ubiquitous liver and fetal isoforms to the heart-type isoforms during early postnatal skeletal muscle maturation in humans and mice. The heart/muscle isoforms become the main forms by around three months in human infants and by four weeks in mice [87]. Heart-type isoforms of C*c*O have been linked to increased mitochondrial capacity compared to liver-type [12,13]. *CcO6a2* knockout mice have cardiac dysfunction [21], and, interestingly, skeletal muscle is protected from insulin resistance and glucose intolerance [88], but no further in-depth mitochondrial studies were carried out for this heart isoform. We previously generated C*c*O7A1-deficient mice and reported an ~50% reduction in total C*c*O activity, and the mice presented with dilated cardiomyopathy [20]. Interestingly, *Cox7a1* knockout mice compensate for loss of C*c*O7A1 by upregulating the liver-type C*c*O7A2 isoform, indicating that an isoform switch is possible. We also reported that loss of C*c*O7A1 specifically impairs dimeric and higher-order SCs-associated C*c*O activity in mouse hearts, while monomeric C*c*O activity remained preserved [89]. The compensatory increase in C*c*O7A2 incorporation in *Cox7a1* knockout mice led to rearrangements that favor CI-containing SCs, which seems to help reduce respiratory dysfunction [89].

Interestingly, in CDs-HSD hearts, we observed a switch from the heart-type to the liver-type isoforms for subunits 6A and 7A (our MS analysis did not show fragments of subunit 8, likely because it is very short and hydrophobic), following the pattern of isoform transitioning to the fetal versions seen in heart failure [57], likely driven by inflammatory signaling causing fibrosis and structural and functional changes in the heart [90]. CDs rats lack NDUFA4 and simultaneously exhibit a marked reduction in C*c*O7A1, therefore, C*c*O dimers are expected to be structurally unstable, and the increase in phosphorylation detected on C*c*O dimers in the sensitive HSD animals suggests an adaptive response to ETC stress. Dimer-selective phosphorylation has been reported as a stress-responsive regulatory mechanism that slows electron flux and may stabilize residual dimeric complexes [16,17,38]. This aligns with the model proposed by Ramzan et al., in which cardiac C*c*O transitions between monomeric and dimeric states via phosphorylation, and inhibitory dimer phosphorylation is reversed upon C*c*O monomerization [91]. Thus, the decrease in C*c*O7A1 may represent an attempt to shift C*c*O towards the more active monomeric form. The increased phosphorylation observed here may reflect a compensatory regulation of structurally compromised C*c*O dimers under the diabetic condition. In summary, we propose that isoform switching and lack of NDUFA4 may compromise the structural integrity required to form functional C*c*O dimers. As a result, increased expression of the liver isoforms cannot rescue C*c*O dimer dysfunction, leading instead to an accumulation of hyperphosphorylated dimers. This state is promoted by inflammatory signaling, resulting in synergistic pathological effects caused by genetic predisposition and diabetic mitochondrial remodeling.

We also found a reduction in C*c*O protein content when the Cohen rats were given the HSD. It should be noted that the HSD is also low in copper, which may in part explain lower C*c*O levels because copper plays an important role in C*c*O biogenesis and function [40]. However, SOD1 is also a copper-dependent protein, and its levels remained unchanged under the HSD, which suggests that factors other than the low copper diet may contribute to a decrease in C*c*O amount, such as changes in the activity or amount of mitochondrial proteases, which should be explored in future studies.

Given the need of cardiac tissue for increased ATP production, quality control mechanisms become critical. A balance between mitochondrial fission and fusion and mitophagy are essential for maintaining cellular health, particularly in the heart [63,92], where high ATP demand prevails. We measured an increase in TFAM levels in CDs-HSD compared to CDr-RD and HSD. However, we did not see an increase in mitochondrial mass or replication. It has been reported that strong increases in TFAM levels can be deleterious,

specifically in heart tissue, where high TFAM-to-mtDNA ratios can lead to decreased mtDNA expression, resulting in dysfunctional OXPHOS and mitochondria [93]. The increase in TFAM in CDs-HSD could further exacerbate mitochondrial dysfunction already present, amplifying the diabetic phenotype.

5. Conclusions

Collectively, our findings describe a multi-layered mechanism by which genetic predisposition and dietary stress converge to impair mitochondrial metabolism (Figure 6). In the diabetes-sensitive strain, the high-sucrose diet exacerbated mitochondrial dysfunction by amplifying inhibitory phosphorylation of C*c*O and altering respiratory supercomplex organization. These defects coincided with impaired fatty-acid oxidation and compromised mitochondrial quality control and isoform switching, together contributing to energy depletion. Further studies are needed to elucidate the upstream signaling pathways that mediate C*c*O phosphorylation and supercomplex remodeling that may uncover new therapeutic targets to restore mitochondrial efficiency and prevent diabetic cardiomyopathy.




Figure 6. Mitochondrial dysfunction in diabetic hearts is influenced by a high sucrose diet and genetic predisposition. Relative influence of diet and genetic predisposition on bioenergetics, quality control, fatty acid oxidation, cytokine levels, C*c*O isoforms, C*c*O activity, ATP levels, and pY304 C*c*O levels.

6. Limitations

A limitation of our study is the use of only male Cohen rats. We previously investigated the sex differences in Cohen rats [30], the male rats exhibited more severe expression of the metabolic diabetic phenotype on the HSD, and that is why they were the focus of our current study. Future work should be done to include the use of female rats and investigate potential sex-specific differences in mitochondrial signaling and regulatory pathways. Moreover, extending these analyses to additional type 2 diabetes models would help establish the generality of these findings beyond the Cohen strain model. Another limitation was the use of qPCR only for markers of inflammation that oftentimes, but not always, correlate with changes in protein levels [94,95]. Finally, future studies should involve

measurements with intact mitochondria such as respiratory control ratio and mitochondrial substrate oxidation rates to better understand mitochondrial coupling and bioenergetics.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/antiox15020248/s1, Figure S1: Diet- and strain-dependent effects on the cardiac proteome, Figure S2: ATP loading control, Figure S3: BN-PAGE was followed by in-gel activity, Figure S4: HSD leads to a decrease in C*c*OI amount, Figure S5: Composition and rearrangement of respiratory supercomplexes (SCs) containing pY304-phosphorylated C*c*O subunit I in heart mitochondria, Figure S6: Quantification of Complex I and Complex III Immunoblot, Figure S7: Total protein from heart was run on an SDS-PAGE followed with immunoblotting from Figure 5. Table S1: Venn Diagram. Table S2: Two-Way ANOVA table.

Author Contributions: M.H., L.P. (Lauren Pavelich), T.A., L.P. (Lucynda Pham), D.K., P.M.S., R.L., A.S. and S.W.-Z. designed and performed experiments. L.P. (Lauren Pavelich), T.A. and M.H. wrote the original draft. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by the Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, by the National Institutes of Health grants R01 GM116807 (M.H.), Israel Science Foundation (ISF) grant # 2432/23, and Chief Scientist Office (Israeli Dairy Board) grant # 3-19245 (S.W.Z.). We acknowledge the assistance of the Wayne State University Proteomics Core that is supported through NIH grants P30ES036084, P30CA022453, and S10OD030484.

Institutional Review Board Statement: Animal experiments were approved under protocol number MD-22-16924-3 by the Institutional Animal Experiments Committee (IACUC).

Informed Consent Statement: Not applicable.

Data Availability Statement: All data generated or analyzed during this study are included in this published article and Supplementary Information Files. The mass spectrometry raw data have been deposited to ProteomeXchange via the PRIDE partner repository; the project accession number is PXD066170.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:

C*c*O, CIV	cytochrome *c* oxidase, complex IV
ETC	electron transport chain
OXPHOS	oxidative phosphorylation
SCs	supercomplexes
PTMs	posttranslational modifications
ATP	adenosine triphosphate
OCR	oxygen consumption reading
ROS	reactive oxygen species
RD	regular diet
HSD	high-sucrose-low-copper diet
CDr	Cohen-diabetic resistant
CDs	Cohen-diabetic sensitive
Y304-C*c*O-I	tyrosine 304 in the catalytic subunit I of C*c*O
pY304	phosphorylated tyrosine 304
T2D	Type 2 diabetes
BN-PAGE	Blue Native-PAGE
IGA	In-gel activity
SC_{pY304}	Supercomplexes containing phosphorylated Y304
CI	Complex I
CII	Complex II

CIII	Complex III
TNFα	Tumor necrosis factor
IL-1β	Interleukin-1 beta
CCL2	C-C motif chemokine ligand 2
CXCL2	chemokine ligand 2
IL-10	Interleukin 10
VDAC	voltage-dependent anion channel
PGC1α	peroxisome proliferator-activated receptor gamma coactivator 1-alpha
SOD1	superoxide dismutase 1
SOD2	superoxide dismutase 2
MFN2	Mitofusin 2
DRP1	Dynamin-related protein 1
pS616	active Dynamin-related protein 1
LC3	microtubule-associated protein light chain 3
p62/SQSTM1	sequestosome 1

References

1. Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K.; Walter, P. *The Molecular Biology of the Cell*; Garland Science: New York, NY, USA, 2002; Volume 4.
2. Liang, C.; Padavannil, A.; Zhang, S.; Beh, S.; Robinson, D.R.L.; Meisterknecht, J.; Cabrera-Orefice, A.; Koves, T.R.; Watanabe, C.; Watanabe, M.; et al. Formation of I_2+III_2 supercomplex rescues respiratory chain defects. *Cell Metab.* **2025**, *37*, 441–459. [CrossRef]
3. Boekema, E.J.; Braun, H.P. Supramolecular structure of the mitochondrial oxidative phosphorylation system. *J. Biol. Chem.* **2007**, *282*, 1–4. [CrossRef]
4. Milenkovic, D.; Blaza, J.N.; Larsson, N.G.; Hirst, J. The Enigma of the Respiratory Chain Supercomplex. *Cell Metab.* **2017**, *25*, 765–776. [CrossRef]
5. Milenkovic, D.; Misic, J.; Hevler, J.F.; Molinie, T.; Chung, I.; Atanassov, I.; Li, X.; Filograna, R.; Mesaros, A.; Mourier, A.; et al. Preserved respiratory chain capacity and physiology in mice with profoundly reduced levels of mitochondrial respirasomes. *Cell Metab.* **2023**, *35*, 1799–1813.e7. [CrossRef]
6. Cogliati, S.; Cabrera-Alarcon, J.L.; Enriquez, J.A. Regulation and functional role of the electron transport chain supercomplexes. *Biochem. Soc. Trans.* **2021**, *49*, 2655–2668. [CrossRef] [PubMed]
7. Vercellino, I.; Sazanov, L.A. Structure and assembly of the mammalian mitochondrial supercomplex $CIII_2CIV$. *Nature* **2021**, *598*, 364–367. [CrossRef]
8. Acin-Perez, R.; Fernandez-Silva, P.; Peleato, M.L.; Perez-Martos, A.; Enriquez, J.A. Respiratory active mitochondrial supercomplexes. *Mol. Cell* **2008**, *32*, 529–539. [CrossRef] [PubMed]
9. Maranzana, E.; Barbero, G.; Falasca, A.I.; Lenaz, G.; Genova, M.L. Mitochondrial respiratory supercomplex association limits production of reactive oxygen species from complex I. *Antioxid. Redox Signal.* **2013**, *19*, 1469–1480. [CrossRef]
10. Harman, D. The biologic clock: The mitochondria? *J. Am. Geriatr. Soc.* **1972**, *20*, 145–147. [CrossRef] [PubMed]
11. Guan, S.; Zhao, L.; Peng, R. Mitochondrial Respiratory Chain Supercomplexes: From Structure to Function. *Int. J. Mol. Sci.* **2022**, *23*, 13880. [CrossRef]
12. Pham, L.; Arroum, T.; Wan, J.; Pavelich, L.; Bell, J.; Morse, P.T.; Lee, I.; Grossman, L.I.; Sanderson, T.H.; Malek, M.H.; et al. Regulation of mitochondrial oxidative phosphorylation through tight control of cytochrome c oxidase in health and disease—Implications for ischemia/reperfusion injury, inflammatory diseases, diabetes, and cancer. *Redox Biol.* **2024**, *78*, 103426. [CrossRef]
13. Sinkler, C.A.; Kalpage, H.; Shay, J.; Lee, I.; Malek, M.H.; Grossman, L.I.; Hüttemann, M. Tissue- and Condition-Specific Isoforms of Mammalian Cytochrome c Oxidase Subunits: From Function to Human Disease. *Oxid. Med. Cell. Longev.* **2017**, *2017*, 1534056. [CrossRef]
14. Arnold, S.; Kadenbach, B. The intramitochondrial ATP/ADP-ratio controls cytochrome c oxidase activity allosterically. *FEBS Lett.* **1999**, *443*, 105–108. [CrossRef]
15. Arnold, S.; Goglia, F.; Kadenbach, B. 3,5-Diiodothyronine binds to subunit Va of cytochrome-c oxidase and abolishes the allosteric inhibition of respiration by ATP. *Eur. J. Biochem.* **1998**, *252*, 325–330. [CrossRef]
16. Lee, I.; Salomon, A.R.; Ficarro, S.; Mathes, I.; Lottspeich, F.; Grossman, L.I.; Hüttemann, M. cAMP-dependent tyrosine phosphorylation of subunit I inhibits cytochrome c oxidase activity. *J. Biol. Chem.* **2005**, *280*, 6094–6100. [CrossRef]
17. Samavati, L.; Lee, I.; Mathes, I.; Lottspeich, F.; Hüttemann, M. Tumor necrosis factor alpha inhibits oxidative phosphorylation through tyrosine phosphorylation at subunit I of cytochrome c oxidase. *J. Biol. Chem.* **2008**, *283*, 21134–21144. [CrossRef]

18. Sangwung, P.; Petersen, K.F.; Shulman, G.I.; Knowles, J.W. Mitochondrial Dysfunction, Insulin Resistance, and Potential Genetic Implications. *Endocrinology* **2020**, *161*, bqaa017. [CrossRef] [PubMed]
19. Boudina, S.; Sena, S.; O'Neill, B.T.; Tathireddy, P.; Young, M.E.; Abel, E.D. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. *Circulation* **2005**, *112*, 2686–2695. [CrossRef] [PubMed]
20. Hüttemann, M.; Klewer, S.; Lee, I.; Pecinova, A.; Pecina, P.; Liu, J.; Lee, M.; Doan, J.W.; Larson, D.; Slack, E.; et al. Mice deleted for heart-type cytochrome c oxidase subunit 7a1 develop dilated cardiomyopathy. *Mitochondrion* **2012**, *12*, 294–304. [CrossRef] [PubMed]
21. Radford, N.B.; Wan, B.; Richman, A.; Szczepaniak, L.S.; Li, J.L.; Li, K.; Pfeiffer, K.; Schagger, H.; Garry, D.J.; Moreadith, R.W. Cardiac dysfunction in mice lacking cytochrome-c oxidase subunit VIaH. *Am. J. Physiol. Heart Circ. Physiol.* **2002**, *282*, H726–H733. [CrossRef]
22. LaMoia, T.E.; Butrico, G.M.; Kalpage, H.A.; Goedeke, L.; Hubbard, B.T.; Vatner, D.F.; Gaspar, R.C.; Zhang, X.M.; Cline, G.W.; Nakahara, K.; et al. Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis. *Proc. Natl. Acad. Sci. USA* **2022**, *119*, e2122287119. [CrossRef]
23. Peng, C.; Zhang, Y.; Lang, X.; Zhang, Y. Role of mitochondrial metabolic disorder and immune infiltration in diabetic cardiomyopathy: New insights from bioinformatics analysis. *J. Transl. Med.* **2023**, *21*, 66. [CrossRef]
24. Vadvalkar, S.S.; Baily, C.N.; Matsuzaki, S.; West, M.; Tesiram, Y.A.; Humphries, K.M. Metabolic inflexibility and protein lysine acetylation in heart mitochondria of a chronic model of type 1 diabetes. *Biochem. J.* **2013**, *449*, 253–261. [CrossRef]
25. Yan, A.; Xie, G.; Ding, X.; Wang, Y.; Guo, L. Effects of Lipid Overload on Heart in Metabolic Diseases. *Horm. Metab. Res.* **2021**, *53*, 771–778. [CrossRef]
26. Dikalov, S.; Panov, A.; Dikalova, A. Critical Role of Mitochondrial Fatty Acid Metabolism in Normal Cell Function and Pathological Conditions. *Int. J. Mol. Sci.* **2024**, *25*, 6498. [CrossRef]
27. Li, W.; Yao, M.; Wang, R.; Shi, Y.; Hou, L.; Hou, Z.; Lian, K.; Zhang, N.; Wang, Y.; Li, W.; et al. Profile of cardiac lipid metabolism in STZ-induced diabetic mice. *Lipids Health Dis.* **2018**, *17*, 231. [CrossRef] [PubMed]
28. Karwi, Q.G.; Sun, Q.; Lopaschuk, G.D. The Contribution of Cardiac Fatty Acid Oxidation to Diabetic Cardiomyopathy Severity. *Cells* **2021**, *10*, 3259. [CrossRef] [PubMed]
29. Wenzl, F.A.; Ambrosini, S.; Mohammed, S.A.; Kraler, S.; Luscher, T.F.; Costantino, S.; Paneni, F. Inflammation in Metabolic Cardiomyopathy. *Front. Cardiovasc. Med.* **2021**, *8*, 742178. [CrossRef]
30. Weksler-Zangen, S.; Yagil, C.; Zangen, D.H.; Ornoy, A.; Jacob, H.J.; Yagil, Y. The newly inbred cohen diabetic rat: A nonobese normolipidemic genetic model of diet-induced type 2 diabetes expressing sex differences. *Diabetes* **2001**, *50*, 2521–2529. [CrossRef] [PubMed]
31. Aharon-Hananel, G.; Romero-Afrima, L.; Saada, A.; Mantzur, C.; Raz, I.; Weksler-Zangen, S. Cytochrome c Oxidase Activity as a Metabolic Regulator in Pancreatic Beta-Cells. *Cells* **2022**, *11*, 929. [CrossRef] [PubMed]
32. Weksler-Zangen, S.; Raz, I.; Lenzen, S.; Jorns, A.; Ehrenfeld, S.; Amir, G.; Oprescu, A.; Yagil, Y.; Yagil, C.; Zangen, D.H.; et al. Impaired glucose-stimulated insulin secretion is coupled with exocrine pancreatic lesions in the Cohen diabetic rat. *Diabetes* **2008**, *57*, 279–287. [CrossRef] [PubMed]
33. Amenta, F.; Peleg, E.; Tomassoni, D.; Sabbatini, M.; Rosenthal, T. Effect of treatment with lercanidipine on heart of Cohen-Rosenthal diabetic hypertensive rats. *Hypertension* **2003**, *41*, 1330–1335. [CrossRef]
34. Yosefy, O.; Sharon, B.; Yagil, C.; Shlapoberski, M.; Livoff, A.; Novitski, I.; Beeri, R.; Yagil, Y.; Yosefy, C. Diabetes induces remodeling of the left atrial appendage independently of atrial fibrillation in a rodent model of type-2 diabetes. *Cardiovasc. Diabetol.* **2021**, *20*, 149. [CrossRef]
35. Cohen, A.M.; Rosenmann, E.; Rosenthal, T. The Cohen diabetic (non-insulin-dependent) hypertensive rat model. Description of the model and pathologic findings. *Am. J. Hypertens.* **1993**, *6*, 989–995. [CrossRef]
36. Vinokur, V.; Weksler-Zangen, S.; Berenshtein, E.; Eliashar, R.; Chevion, M. The Loss of Myocardial Benefit following Ischemic Preconditioning Is Associated with Dysregulation of Iron Homeostasis in Diet-Induced Diabetes. *PLoS ONE* **2016**, *11*, e0159908. [CrossRef]
37. Kogot-Levin, A.; Saada, A.; Leibowitz, G.; Soiferman, D.; Douiev, L.; Raz, I.; Weksler-Zangen, S. Upregulation of Mitochondrial Content in Cytochrome c Oxidase Deficient Fibroblasts. *PLoS ONE* **2016**, *11*, e0165417. [CrossRef]
38. Arroum, T.; Pham, L.; Raisanen, T.E.; Morse, P.T.; Wan, J.; Bell, J.; Lax, R.; Saada, A.; Hüttemann, M.; Weksler-Zangen, S. High Sucrose Diet-Induced Subunit I Tyrosine 304 Phosphorylation of Cytochrome c Oxidase Leads to Liver Mitochondrial Respiratory Dysfunction in the Cohen Diabetic Rat Model. *Antioxidants* **2024**, *13*, 19. [CrossRef]
39. Weksler-Zangen, S.; Aharon-Hananel, G.; Mantzur, C.; Aouizerat, T.; Gurgul-Convey, E.; Raz, I.; Saada, A. IL-1beta hampers glucose-stimulated insulin secretion in Cohen diabetic rat islets through mitochondrial cytochrome c oxidase inhibition by nitric oxide. *Am. J. Physiol. Endocrinol. Metab.* **2014**, *306*, E648–E657. [CrossRef]

40. Weksler-Zangen, S.; Jorns, A.; Tarsi-Chen, L.; Vernea, F.; Aharon-Hananel, G.; Saada, A.; Lenzen, S.; Raz, I. Dietary copper supplementation restores beta-cell function of Cohen diabetic rats: A link between mitochondrial function and glucose-stimulated insulin secretion. *Am. J. Physiol. Endocrinol. Metab.* **2013**, *304*, E1023–E1034. [CrossRef] [PubMed]
41. Zhang, S.; Liu, H.; Amarsingh, G.V.; Cheung, C.C.; Hogl, S.; Narayanan, U.; Zhang, L.; McHarg, S.; Xu, J.; Gong, D.; et al. Diabetic cardiomyopathy is associated with defective myocellular copper regulation and both defects are rectified by divalent copper chelation. *Cardiovasc. Diabetol.* **2014**, *13*, 100. [CrossRef] [PubMed]
42. Cui, X.; Wang, Y.; Liu, H.; Shi, M.; Wang, J.; Wang, Y. The Molecular Mechanisms of Defective Copper Metabolism in Diabetic Cardiomyopathy. *Oxid. Med. Cell. Longev.* **2022**, *2022*, 5418376. [CrossRef]
43. Tyanova, S.; Temu, T.; Cox, J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. *Nat. Protoc.* **2016**, *11*, 2301–2319. [CrossRef]
44. Tyanova, S.; Temu, T.; Sinitcyn, P.; Carlson, A.; Hein, M.Y.; Geiger, T.; Mann, M.; Cox, J. The Perseus computational platform for comprehensive analysis of (prote)omics data. *Nat. Methods* **2016**, *13*, 731–740. [CrossRef]
45. Jha, P.; Wang, X.; Auwerx, J. Analysis of Mitochondrial Respiratory Chain Supercomplexes Using Blue Native Polyacrylamide Gel Electrophoresis (BN-PAGE). *Curr. Protoc. Mouse Biol.* **2016**, *6*, 1–14. [CrossRef] [PubMed]
46. Ding, L.; Wu, J.; Li, D.; Wang, H.; Zhu, B.; Lu, W.; Xu, G. Effects of CCN3 on rat cartilage endplate chondrocytes cultured under serum deprivation in vitro. *Mol. Med. Rep.* **2016**, *13*, 2017–2022. [CrossRef] [PubMed]
47. Peinnequin, A.; Mouret, C.; Birot, O.; Alonso, A.; Mathieu, J.; Clarencon, D.; Agay, D.; Chancerelle, Y.; Multon, E. Rat pro-inflammatory cytokine and cytokine related mRNA quantification by real-time polymerase chain reaction using SYBR green. *BMC Immunol.* **2004**, *5*, 3. [CrossRef]
48. Tong, H.H.; Chen, Y.; Liu, X.; DeMaria, T.F. Differential expression of cytokine genes and iNOS induced by nonviable nontypeable Haemophilus influenzae or its LOS mutants during acute otitis media in the rat. *Int. J. Pediatr. Otorhinolaryngol.* **2008**, *72*, 1183–1191. [CrossRef] [PubMed]
49. Long, J.P.; Tong, H.H.; Shannon, P.A.; DeMaria, T.F. Differential expression of cytokine genes and inducible nitric oxide synthase induced by opacity phenotype variants of Streptococcus pneumoniae during acute otitis media in the rat. *Infect. Immun.* **2003**, *71*, 5531–5540. [CrossRef]
50. Mateu, A.; De Dios, I.; Manso, M.A.; Ramudo, L. Oxidized phospholipids exert a dual effect on bile acid-induced CCL2 expression in pancreatic acini. *Pancreatology* **2017**, *17*, 372–380. [CrossRef]
51. Rehman, I.U.; Saleem, M.; Raza, S.A.; Bashir, S.; Muhammad, T.; Asghar, S.; Qamar, M.U.; Shah, T.A.; Bin Jardan, Y.A.; Mekonnen, A.B.; et al. Anti-ulcerative colitis effects of chemically characterized extracts from Calliandra haematocephala in acetic acid-induced ulcerative colitis. *Front. Chem.* **2024**, *12*, 1291230. [CrossRef]
52. Yagil, Y.; Markus, B.; Kohen, R.; Yagil, C. Three interacting genomic loci incorporating two novel mutations underlie the evolution of diet-induced diabetes. *Mol. Med.* **2016**, *22*, 560–569. [CrossRef]
53. Yagil, C.; Varadi-Levi, R.; Ifrach, C.; Yagil, Y. Dysregulated UPR and ER Stress Related to a Mutation in the Sdf2l1 Gene Are Involved in the Pathophysiology of Diet-Induced Diabetes in the Cohen Diabetic Rat. *Int. J. Mol. Sci.* **2023**, *24*, 1355. [CrossRef] [PubMed]
54. Balsa, E.; Marco, R.; Perales-Clemente, E.; Szklarczyk, R.; Calvo, E.; Landazuri, M.O.; Enriquez, J.A. NDUFA4 is a subunit of complex IV of the mammalian electron transport chain. *Cell Metab.* **2012**, *16*, 378–386. [CrossRef]
55. Pitceathly, R.D.; Rahman, S.; Wedatilake, Y.; Polke, J.M.; Cirak, S.; Foley, A.R.; Sailer, A.; Hurles, M.E.; Stalker, J.; Hargreaves, I.; et al. NDUFA4 mutations underlie dysfunction of a cytochrome c oxidase subunit linked to human neurological disease. *Cell Rep.* **2013**, *3*, 1795–1805. [CrossRef] [PubMed]
56. Misceo, D.; Stromme, P.; Bitarafan, F.; Chawla, M.S.; Sheng, Y.; Bach de Courtade, S.M.; Eide, L.; Frengen, E. Biallelic NDUFA4 Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome. *Genes* **2024**, *15*, 500. [CrossRef]
57. D'Antonio, M.; Nguyen, J.P.; Arthur, T.D.; Matsui, H.; Donovan, M.K.R.; D'Antonio-Chronowska, A.; Frazer, K.A. In heart failure reactivation of RNA-binding proteins is associated with the expression of 1523 fetal-specific isoforms. *PLoS Comput. Biol.* **2022**, *18*, e1009918. [CrossRef]
58. Yu, S.; Cheng, Y.; Zhang, L.; Yin, Y.; Xue, J.; Li, B.; Gong, Z.; Gao, J.; Mu, Y. Treatment with adipose tissue-derived mesenchymal stem cells exerts anti-diabetic effects, improves long-term complications, and attenuates inflammation in type 2 diabetic rats. *Stem Cell Res. Ther.* **2019**, *10*, 333. [CrossRef] [PubMed]
59. Atici, A.E.; Crother, T.R.; Noval Rivas, M. Mitochondrial quality control in health and cardiovascular diseases. *Front. Cell Dev. Biol.* **2023**, *11*, 1290046. [CrossRef]
60. Nakamura, K.; Miyoshi, T.; Yoshida, M.; Akagi, S.; Saito, Y.; Ejiri, K.; Matsuo, N.; Ichikawa, K.; Iwasaki, K.; Naito, T.; et al. Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus. *Int. J. Mol. Sci.* **2022**, *23*, 3587. [CrossRef]
61. Jankauskas, S.S.; Kansakar, U.; Varzideh, F.; Wilson, S.; Mone, P.; Lombardi, A.; Gambardella, J.; Santulli, G. Heart failure in diabetes. *Metabolism* **2021**, *125*, 154910. [CrossRef]

62. Dillmann, W.H. Diabetic Cardiomyopathy. *Circ. Res.* **2019**, *124*, 1160–1162. [CrossRef]
63. Tong, M.; Saito, T.; Zhai, P.; Oka, S.I.; Mizushima, W.; Nakamura, M.; Ikeda, S.; Shirakabe, A.; Sadoshima, J. Mitophagy Is Essential for Maintaining Cardiac Function During High Fat Diet-Induced Diabetic Cardiomyopathy. *Circ. Res.* **2019**, *124*, 1360–1371. [CrossRef]
64. Hu, L.; Ding, M.; Tang, D.; Gao, E.; Li, C.; Wang, K.; Qi, B.; Qiu, J.; Zhao, H.; Chang, P.; et al. Targeting mitochondrial dynamics by regulating Mfn2 for therapeutic intervention in diabetic cardiomyopathy. *Theranostics* **2019**, *9*, 3687–3706. [CrossRef]
65. Vasquez-Trincado, C.; Garcia-Carvajal, I.; Pennanen, C.; Parra, V.; Hill, J.A.; Rothermel, B.A.; Lavandero, S. Mitochondrial dynamics, mitophagy and cardiovascular disease. *J. Physiol.* **2016**, *594*, 509–525. [CrossRef] [PubMed]
66. Tao, L.C.; Wang, T.T.; Zheng, L.; Hua, F.; Li, J.J. The Role of Mitochondrial Biogenesis Dysfunction in Diabetic Cardiomyopathy. *Biomol. Ther.* **2022**, *30*, 399–408. [CrossRef]
67. Chang, X.; Li, Y.; Cai, C.; Wu, F.; He, J.; Zhang, Y.; Zhong, J.; Tan, Y.; Liu, R.; Zhu, H.; et al. Mitochondrial quality control mechanisms as molecular targets in diabetic heart. *Metabolism* **2022**, *137*, 155313. [CrossRef]
68. Mazumder, P.K.; O'Neill, B.T.; Roberts, M.W.; Buchanan, J.; Yun, U.J.; Cooksey, R.C.; Boudina, S.; Abel, E.D. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. *Diabetes* **2004**, *53*, 2366–2374. [CrossRef] [PubMed]
69. Carley, A.N.; Severson, D.L. Fatty acid metabolism is enhanced in type 2 diabetic hearts. *Biochim. Biophys. Acta* **2005**, *1734*, 112–126. [CrossRef] [PubMed]
70. Fillmore, N.; Mori, J.; Lopaschuk, G.D. Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. *Br. J. Pharmacol.* **2014**, *171*, 2080–2090. [CrossRef]
71. Bharathi, S.S.; Zhang, Y.; Mohsen, A.W.; Uppala, R.; Balasubramani, M.; Schreiber, E.; Uechi, G.; Beck, M.E.; Rardin, M.J.; Vockley, J.; et al. Sirtuin 3 (SIRT3) protein regulates long-chain acyl-CoA dehydrogenase by deacetylating conserved lysines near the active site. *J. Biol. Chem.* **2013**, *288*, 33837–33847. [CrossRef]
72. Chen, T.; Liu, J.; Li, N.; Wang, S.; Liu, H.; Li, J.; Zhang, Y.; Bu, P. Mouse SIRT3 attenuates hypertrophy-related lipid accumulation in the heart through the deacetylation of LCAD. *PLoS ONE* **2015**, *10*, e0118909. [CrossRef]
73. Pitceathly, R.D.S.; Taanman, J.W. NDUFA4 (Renamed COXFA4) Is a Cytochrome-c Oxidase Subunit. *Trends Endocrinol. Metab.* **2018**, *29*, 452–454. [CrossRef]
74. Smith, A.; McCulloh, R.J. Hemopexin and haptoglobin: Allies against heme toxicity from hemoglobin not contenders. *Front. Physiol.* **2015**, *6*, 187. [CrossRef]
75. Liu, Z.; Wang, M.; Zhang, C.; Zhou, S.; Ji, G. Molecular Functions of Ceruloplasmin in Metabolic Disease Pathology. *Diabetes Metab. Syndr. Obes.* **2022**, *15*, 695–711. [CrossRef]
76. Dalan, R.; Liuh Ling, G. The protean role of haptoglobin and haptoglobin genotypes on vascular complications in diabetes mellitus. *Eur. J. Prev. Cardiol.* **2018**, *25*, 1502–1519. [CrossRef]
77. Zhu, L.; Giunzioni, I.; Tavori, H.; Covarrubias, R.; Ding, L.; Zhang, Y.; Ormseth, M.; Major, A.S.; Stafford, J.M.; Linton, M.F.; et al. Loss of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 Confers Resistance to the Antiatherogenic Effects of Tumor Necrosis Factor-alpha Inhibition. *Arterioscler. Thromb. Vasc. Biol.* **2016**, *36*, 1483–1495. [CrossRef] [PubMed]
78. Moyer, C.F.; Sajuthi, D.; Tulli, H.; Williams, J.K. Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. *Am. J. Pathol.* **1991**, *138*, 951–960. [PubMed]
79. Dusi, V.; Ghidoni, A.; Ravera, A.; De Ferrari, G.M.; Calvillo, L. Chemokines and Heart Disease: A Network Connecting Cardiovascular Biology to Immune and Autonomic Nervous Systems. *Mediat. Inflamm.* **2016**, *2016*, 5902947. [CrossRef] [PubMed]
80. Cassidy, S.; Hallsworth, K.; Thoma, C.; MacGowan, G.A.; Hollingsworth, K.G.; Day, C.P.; Taylor, R.; Jakovljevic, D.G.; Trenell, M.I. Cardiac structure and function are altered in type 2 diabetes and non-alcoholic fatty liver disease and associate with glycemic control. *Cardiovasc. Diabetol.* **2015**, *14*, 23. [CrossRef]
81. Brown, D.A.; Perry, J.B.; Allen, M.E.; Sabbah, H.N.; Stauffer, B.L.; Shaikh, S.R.; Cleland, J.G.; Colucci, W.S.; Butler, J.; Voors, A.A.; et al. Expert consensus document: Mitochondrial function as a therapeutic target in heart failure. *Nat. Rev. Cardiol.* **2017**, *14*, 238–250. [CrossRef]
82. Rui, L. Energy metabolism in the liver. *Compr. Physiol.* **2014**, *4*, 177–197. [CrossRef] [PubMed]
83. Garcia-Poyatos, C.; Cogliati, S.; Calvo, E.; Hernansanz-Agustin, P.; Lagarrigue, S.; Magni, R.; Botos, M.; Langa, X.; Amati, F.; Vazquez, J.; et al. Scaf1 promotes respiratory supercomplexes and metabolic efficiency in zebrafish. *EMBO Rep.* **2020**, *21*, e50287. [CrossRef] [PubMed]
84. Muller, C.S.; Bildl, W.; Haupt, A.; Ellenrieder, L.; Becker, T.; Hunte, C.; Fakler, B.; Schulte, U. Cryo-slicing Blue Native-Mass Spectrometry (csBN-MS), a Novel Technology for High Resolution Complexome Profiling. *Mol. Cell. Proteom.* **2016**, *15*, 669–681. [CrossRef]
85. Calvo, E.; Cogliati, S.; Hernansanz-Agustin, P.; Loureiro-Lopez, M.; Guaras, A.; Casuso, R.A.; Garcia-Marques, F.; Acin-Perez, R.; Marti-Mateos, Y.; Silla-Castro, J.C.; et al. Functional role of respiratory supercomplexes in mice: SCAF1 relevance and segmentation of the Q(pool). *Sci. Adv.* **2020**, *6*, eaba7509. [CrossRef] [PubMed]

86. Hüttemann, M.; Schmidt, T.R.; Grossman, L.I. A third isoform of cytochrome c oxidase subunit VIII is present in mammals. *Gene* **2003**, *312*, 95–102. [CrossRef]
87. Boczonadi, V.; Giunta, M.; Lane, M.; Tulinius, M.; Schara, U.; Horvath, R. Investigating the role of the physiological isoform switch of cytochrome c oxidase subunits in reversible mitochondrial disease. *Int. J. Biochem. Cell Biol.* **2015**, *63*, 32–40. [CrossRef]
88. Quintens, R.; Singh, S.; Lemaire, K.; De Bock, K.; Granvik, M.; Schraenen, A.; Vroegrijk, I.O.; Costa, V.; Van Noten, P.; Lambrechts, D.; et al. Mice deficient in the respiratory chain gene Cox6a2 are protected against high-fat diet-induced obesity and insulin resistance. *PLoS ONE* **2013**, *8*, e56719. [CrossRef]
89. Pavelich, L.; Pham, L.; Stemmer, P.; Lee, I.; Grossman, L.I.; Hüttemann, M.; Arroum, T. Supercomplex Restructuring in Heart Mitochondria of COX7A1-Deficient Mice. *Biomolecules* **2025**, *15*, 1209. [CrossRef]
90. Burke, M.A.; Chang, S.; Wakimoto, H.; Gorham, J.M.; Conner, D.A.; Christodoulou, D.C.; Parfenov, M.G.; DePalma, S.R.; Eminaga, S.; Konno, T.; et al. Molecular profiling of dilated cardiomyopathy that progresses to heart failure. *JCI Insight* **2016**, *1*, e86898. [CrossRef]
91. Ramzan, R.; Rhiel, A.; Weber, P.; Kadenbach, B.; Vogt, S. Reversible dimerization of cytochrome c oxidase regulates mitochondrial respiration. *Mitochondrion* **2019**, *49*, 149–155. [CrossRef]
92. Tong, M.; Zablocki, D.; Sadoshima, J. The role of Drp1 in mitophagy and cell death in the heart. *J. Mol. Cell. Cardiol.* **2020**, *142*, 138–145. [CrossRef] [PubMed]
93. Bonekamp, N.A.; Jiang, M.; Motori, E.; Garcia Villegas, R.; Koolmeister, C.; Atanassov, I.; Mesaros, A.; Park, C.B.; Larsson, N.G. High levels of TFAM repress mammalian mitochondrial DNA transcription in vivo. *Life Sci. Alliance* **2021**, *4*, e202101034. [CrossRef]
94. Du, H.W.; Chen, G.Y.; Yang, C.H.; Li, C.B.; Xun, Y.P.; Liu, J.; Chen, P.; Shi, L.L. Multiple correlations of mRNA expression and protein abundance in human cytokine profile. *Mol. Biol. Rep.* **2014**, *41*, 6985–6993. [CrossRef] [PubMed]
95. Shebl, F.M.; Pinto, L.A.; Garcia-Pineres, A.; Lempicki, R.; Williams, M.; Harro, C.; Hildesheim, A. Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles. *Cancer Epidemiol. Biomark. Prev.* **2010**, *19*, 978–981. [CrossRef] [PubMed]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.